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SUMMARY
Fulminant hepatic failure is a condition associated with a 
high mortality. The experience of its treatment over a 26 
month period in a referral unit for acute liver failure is 
reviewed. The overall mortality rate was 45% but for those 
who progressed to grade IV hepatic coma the mortality rate 
was 73%. These figures represent the results of a 
combination of medical management and liver 
transplantation. The largest group of patients referred had 
developed liver failure due to ingestion of paracetamol 
(55%), the next largest group had viral hepatitis, mainly 
non A non B hepatitis (25%) and the others had an 
assortment of aetiologies including acute Budd-Chiari 
syndrome and other drug reactions. These different 
aetiological groups have been considered separately and 
predictors of outcome determined from their admission and 
early clinical and laboratory results. In the paracetamol 
group degree of coma, bilirubin and creatinine levels, 
hydrogen ion concentration and prothrombin ratio proved to 
be useful prognostic indicators but in the other two groups 
these measurements bore no relationship to the ultimate 
outcome.
Past and present treatments of fulminant hepatic failure 
are then reviewed with discussion of the timing and long 
term consequences of orthotopic liver transplatation. The 
history of hepatocyte transplantation is presented with 
particular reference to its use in acute hepatic failure in 
experimental animals. Reference is made to studies
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suggesting that intact hepatocytes are not required to 
improve survival of the animals but that subcellular 
fractions from regenerating livers are as effective at 
improving survival. Cytosol from nonregenerating liver has 
in the past been shown to be ineffective at improving the 
animals' survival.
A model of acute liver failure using a single 
intraperitoneal injection of dimethylnitrosamine was 
developed in the Wistar rat and produced a reproducible 
degree of liver necrosis. This model was then used ih all 
subsequent in vivo experiments.
Hepatocyte transplantation was investigated using the 
intrasplenic route or by intraperitoneal injection. Neither 
of these treatment modalities significantly improved the 
survival or any of the other measured indices of severity 
(blood coagulation, biochemical liver function tests or 
extent of hepatocyte necrosis) when compared with the 
control groups. Two of the rats treated with 
intraperitoneal hepatocytes did survive to show full 
recovery from liver failure and clumps of intact 
hepatocytes were found in the peritoneal cavity at post 
mortem. Some of these cells appeared on light microscopy to 
be viable but the deposits also contained some dead cells. 
This finding is contrary to the work of other researchers 
who have failed to detect any evidence of cells, either 
dead or alive, when they have been transplanted by this 
route.
The hepatocytes which had been prepared by in situ 
collagenase perfusion of the liver were then disrupted by 
ultrasound bombardment and ultracentrifuged to obtain 
hepatocyte cytosol. This was injected intraperitoneally in 
repeated doses to the rats with liver failure and there was 
a significant improvement in animal survival compared with 
the control group. This effect may have been even greater 
but some of the rats developed fatal intraperitoneal 
haemorrhage because of the repeated injections during a 
time of defective blood coagulation.
Cytosol was then given by repeated intravenous injection 
and this produced a significant improvement in survival 
with 75% of the rats recovering. Different doses of cytosol 
were tried and the improvement was evident over the three 
doses tested. When plasma was given the result for this was 
midway between the cytosol and saline (control) groups and 
not significantly different from either. Further 
experiments showed the cytosol to be effective if 
administered up to 24 hours after the induction of liver 
failure. In a paired experiment where the cytosol treated 
rat was sacrificed at the time of death of its control rat 
no significant difference was seen in the amount of liver 
necrosis but there was significantly more cellular 
regeneration in the surviving hepatocytes in the cytosol 
treated rats.
Human hepatocyte cytosol was also used in the rat model and 
produced a similar improvement in survival showing that the
10
substance responsible for this improvement is also present 
in human liver cytosol.
Rat cytosol was heated at over 56°C and another sample 
dialysed across a small pore membrane and the fractions 
tested in the liver failure model. The results of this 
suggested that the active substance is a molecule of* 
molecular weight below 8,000 daltons and is heat labile.
Both rat and human cytosols were added to hepatocytes in 
cell culture and changes in the amount of DNA synthesis 
measured. Neither of the cytosols produced a demonstrable 
change, suggesting no increase in cell regeneration.
A possible explanation for these findings is that by using 
pure hepatocyte cytosol this preparation is not 
contaminated by cytosol from nonparenchymal cells as the 
liver cytosol produced by homogenization of liver slices 
used by other workers must be. This could be the reason 
that my cytosol from nonregenerative liver is effective 
treatment of liver failure and that the contribution from 
the Kupffer and endothelial cells is what is inhibitory to 
cell growth. The factor producing the beneficial effect is 
obviously not acting directly on the hepatocytes to 
stimulate increased regeneration but must require an 
interaction with other tissues (possibly the 
reticuloendothelial system) in the intact animal to produce 
its effect.
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Liver transplantation is at present the best therapy for 
clinical fulminant hepatic failure but is not appropriate 
for all patients and is not without long term morbidity. 
Alternative treatments to support the failed liver or 
increase regeneration of the surviving hepatocytes require 
to be found and developed. In this thesis a method of 
producing hepatocyte cytosol is described and its 
administration to rats with acute liver failure is 
reported. When given intravenously in repeated doses it 
improves the survival of the animals and appears to do so 
by stimulating regeneration. If this technique could be 
applied to humans it might improve the prognosis for some 
patients with fulminant hepatic failure.
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INTRODUCTION
Fulminant hepatic failure has been defined by Trey and 
Davidson (1970) as the development of hepatic 
encephalopathy within 8 weeks of the onset of liver 
failure. It poses a major problem for the clinician because 
of its considerable mortality when treated medically 
(Vickers 1988).
Within the last 5 years there has been the treatment"option 
of liver transplantation which can give better patient 
survival rates. Unfortunately a donor liver is not always 
available at the most appropriate time. Even if an organ 
can be found, it may not be the most suitable for the 
intended recipient, in terms of size, age, ABO blood group, 
or be from a suboptimal donor. Not all patients with acute 
liver failure are suitable candidates for liver 
transplantation and decisions require to be made about 
which patients should be offered this treatment. A further 
weakness of orthotopic transplantation as treatment is that 
it involves immunosuppressive therapy for the rest of the 
patient's life. This carries an increased susceptibility to 
infection and malignancy. Episodes of graft rejection and 
possible loss of the liver from this make transplantation 
less than the ideal solution to the management of hepatic 
failure.
Numerous liver support systems have been tried but the 
initially reported improved survivals have not stood up to
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critical study, neither would many achieve public 
acceptability.
Hepatocellular transplantation showed promise as a possible 
solution to the problem but despite initial enthusiasm 
these attempts have not been adapted to the clinical 
situation.
In this study clinical experience in the Liver Unit of the 
Queen Elizabeth Hospital was recorded over a 2 year period. 
Then experiments are undertaken to develop an animal model 
of acute liver failure and to use this to explore different 
treatments of liver failure. Isolated hepatocytes were 
transplanted and then subcellular components of the 
hepatocytes from normal (nonregenerating) liver were 
injected. Different routes of administration of both cells 
and cytosol were also explored.
By these methods it is hoped to develop a readily
available, easily administered, effective, temporary 
therapy for acute liver failure which has the potential for
adaptation to the human situation.
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AIM
i) to assess the number of, and result of therapy in, 
patients presenting with and developing acute hepatic 
failure and to investigate the potential help of prognostic 
factors in their management;
ii) to set up and validate a model of acute hepatic failure 
in a small animal;
iii) by means of hepatocyte transplantation or injection of 
hepatocyte-derived products by various routes to alter the 
outcome of the hepatic failure in relation to survival, the 
rate of recovery of clotting factor synthesis, biochemical 
liver function tests and histopathological features;
iv) to attempt partial physical and chemical purification 
of any substances proving effective;
v) to test cell-derived substances in vitro by their effect 
on DNA synthesis in hepatocyte culture.
vi) to determine if any substance found in rats is present 
in human hepatocytes.
15
ACUTE HEPATIC FAILURE - A CLINICAL PERSPECTIVE
Fulminant hepatic failure as defined by Trey and Davidson 
(1970) is a syndrome of failure of liver function with the 
development of hepatic encephalopathy within 8 weeks of the 
onset of the illness in a person with no previous liver 
disease. It is associated with a considerable mortality and 
even when treated aggressively survival rates only reach 
20-30% by conventional medical management (Vickers 1988) . 
The advent of hepatic transplantation has given a lifeline 
to some of these patients but the supply of donor organs is 
not sufficient to provide adequate numbers of livers for 
these emergency transplantations as well as supporting the 
ever increasing demand from patients with chronic hepatic 
diseases. The extent of the need for emergency liver 
replacement must be discerned, with identification of the 
patients most likely to benefit from the limited resources, 
and other methods of supporting the temporarily failing 
liver found.
Attempts to help this problem have been made by Christensen 
(1984), Tygstrup (1986) and O'Grady (1989) by defining 
those subgroups of patients with acute liver failure who 
have the worst prognosis, and identifying patients who 
cannot be expected to recover adequate hepatic function. 
Those factors which principally affect the outcome are the 
age of the patient (with older and younger people faring 
worse) and the underlying aetiology (with patients who have 
taken a paracetamol overdose usually recovering better than 
those who have viral hepatitis). Even within the types of
16
viral hepatitis those with non A non B hepatitis have a 
greater mortality than those with hepatitis A or hepatitis 
B.
In an attempt to investigate the numbers involved, all 
patients with acute liver failure referred to a 
supraregional liver unit were studied.
Patients and methods
From the beginning of January 1987 till the end of February 
1989, 89 patients with acute hepatic failure were admitted 
to the liver unit at the Queen Elizabeth Hospital in 
Birmingham. All were treated by conventional medical means 
with attention to the fluid balance, controlled by central 
venous pressure monitoring; correction of hypoglycaemia, by 
the infusion of 50% dextrose solution; supplementation of 
blood clotting factors with fresh frozen plasma to avoid 
spontaneous haemorrhage; renal dialysis, either peritoneal 
or haemodialysis if needed to compensate for inadequate 
renal function and mechanical ventilation if the 
respiratory function of the patient was unable to ensure 
satisfactory oxygenation. They received enteral lactulose, 
intravenous ranitidine and vitamin K. Signs of raised 
intracranial pressure detected clinically or by 
intracranial pressure monitoring were treated by 
intermittent boluses of intravenous mannitol and/or by 
controlled hyperventilation.
17
Paracetamol levels were measured, often in the referring 
hospital, in all patients in whom drug overdose was 
considered likely and a full drug history was obtained from 
the patient or family. Other causes of acute liver failure 
were sought including diagnostic investigations for 
Wilson's disease, acute viral infections; hepatitis A and B 
serology, and also for cytomegalovirus and Epstein Barr 
virus. Radiological investigations such as ultrasound and 
angiograghy were used to diagnose such conditions as-Budd- 
Chiari syndrome. The clinical and laboratory measurements 
previously shown by other groups (O'Grady 1989) to indicate 
disease outcome; age, aetiology, extent of hepatic coma, 
clotting derangement as measured by the prothrombin ratio, 
transaminase and bilirubin levels, white cell count, 
hydrogen ion concentration and serum creatinine were 
measured on admission and daily thereafter. These 
measurements were analysed, both by admission values and 
the most abnormal value in the first 48 hours in the unit. 
The time until admission from onset of symptoms or taking 
of a drug overdose was recorded. Whether the patients who 
had taken paracetamol were treated with acetylcysteine was 
also noted..
Some of the patients were considered for liver replacement. 
Whether they received a hepatic transplant, died while 
awaiting a donor organ or recovered without transplantation 
was recorded, as was the ultimate outcome of the episode of 
liver failure.
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Results
During the 26 months, 89 patients with acute hepatic 
failure were admitted. The median age was 31 years with a 
range of 18 months to 66 years and there were 25 males and 
64 females. 48 patients had taken paracetamol overdoses, 23 
had viral hepatitis of which 3 were due to hepatitis B 
infection and the others, by exclusion, diagnosed as non A 
non B hepatitis. 18 patients had other causes for their 
hepatic failure including 6 with other drug causes, usually 
idiosyncratic reactions, 4 with acute Budd-Chiari syndrome, 
2 women who developed liver failure post partum, 2 patients 
whose hepatic failure followed surgery and/or anaesthesia, 
and one patient each with Hodgkin's lymphoma, alcoholic 
hepatitis, a haematological problem and one lady who 
developed acute veno-occlusive disease of the liver 
following a bone marrow transplant for leukaemia.
In the total group, 49 patients survived (55%). Of the 3 7 
patients who developed grade IV hepatic coma 10 recovered 
giving a mortality rate in this most severe group of 73%.
The different aetiological groups will now be considered 
separately.
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Paracetamol overdose
48 patients were admitted with hepatic failure due to 
paracetamol. One claimed to have taken large doses over a 
period of time to treat severe headaches but the rest took 
the tablets at one or occasionally two episodes because of 
psychological or emotional stress. 36 (75%) of this group 
were female. 20 of these patients developed fulminant 
hepatic failure with progression to grade IV coma. The 
overall mortality rate for this group was 35% with 17 of 
the patients dying, but in the fulminant subgroup the 
mortality rate was 75% (15 of 20). The overall survival of 
the females was 61% and 75% for the males. 47% of the 
females developed fulminant failure compared with 25% of 
the males.
Whether or not the patient received acetylcysteine was not 
known in 8 of the cases but of the other 40, 13 were given 
this treatment. Most of the patients not treated with this 
drug attended hospital too late for it to be considered 
effective. The median time from overdose to admission to 
the liver unit was 3 days with a range of 1 to 5 days. Most 
of the patients were referred from other hospitals having 
presented there at least 2 days after taking the tablets.
3 of these patients were considered for liver 
transplantation. One died before a donor liver could be 
found, one underwent a liver transplant but despite . 
postoperative evidence of function in the graft she failed 
to recover neurologically and was found to have sustained
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cerebral coning. The third patient recovered without a 
transplant.
The survivors and non survivors were compared with 
reference to the prognostic factors discussed and the 
results shown in table 1. (median and range given for each 
variable)
Table 1 survivors non survivors signif.
age 25 (14-46) 31 (14-56) N.S.
sex F/M 22/9 F/M 14/3
admission 
coma grade 1 (1-4) 3 (1-4) p<0.005
AST 4470 (619-12000) 5126 (2826-14000) N.S.
bilirubin 64 (13-128) 96 (71-129) p<0.05
H+ conc. 33 (30-37) 42 (37-81) p<0.05
PT ratio 4 (1.5-9) 5 (3-15) p<0.02
WBC 13 (6-20) 16 (7-26) N.S.
creatinine 110 (54-533) 274 (95-415) p<0.05
first 48 hrs 
coma grade 1 (1-4) 4 (2-4) p<0.005
AST 3339 (435-12000) 6133 (3000-14000) p<0.05
bilirubin 108 (18-290) 154 (103-235) p<0.05
H+ conc 31 (28-37) 41 (30-81) p<0.05
PT ratio 4 (1.5-12) 6 (3-15) N.S.
WBC 15 (6-20) 17 (5-28) N.S.
creatinine 108 (67-756) 516 (95-852) p<0.05
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Viral hepatitis
Of the 23 patients who presented with viral hepatitis 3 
were infected with hepatitis B virus, none with hepatitis A 
and by exclusion the remainder were considered to by 
suffering from non A non B hepatitis. When these patients 
presented and this study was undertaken serological testing 
for hepatitis C was not routinely available and so this 
cannot be considered as a separate diagnosis.
11 of the patients (48%) developed grade IV coma and this 
subgroup had a mortality of 64% compared with a mortality 
rate of 52% for the whole group. 17 people received liver 
transplants, 10 of them once they had deteriorated to grade 
IV coma and the other 7 before this stage but with 
indications of a deteriorating course. Of the patients 
transplanted in grade IV coma 4 survived (40%) compared 
with 4 of 7 surviving if transplanted before they reached 
this stage. Three other patients were considered for 
transplantation but died before a donor organ could be 
found. There were 8 males and 15 females in this group with 
ages from 18 months to 60 years (median 35 years). The 
prognostic factors for this aetiological group between the 
survivors and non survivors are compared in table 2.
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Table 2 survivors non
age 41 (1.5-60) 35
sex F/M 8/2 F/M
admission 
coma grade 4 (3-4) 4
AST 1176 (925-1241) 296
bilirubin 594 (340-607) 625
H+conc. 35 - 28
PT ratio 2.5 (2-4) 3
WBC 10 (5-16) 11
creatinine 86 (77-356) 80
first 48 hrs 
coma grade 4 (3-4) 3.5
AST 1050 (796-1241) 305
bilirubin 633 (377-796) 672
H+conc. 31.5 (29-34) 27.5
PT ratio 3.5 (2-6.5) 3.4
WBC 9 (5-16) 11
creatinine 180 (80-356) 124
 survivors signif
-57) N.S.
1-4)
107-5000)
532-900)
1-9)
6- 20)
68-144)
1-4)
107-5000)
365-900)
1- 11)
7-20)
90-309)
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N'.S
N.S
N.S
N.S
Other causes
This group of 18 patients had a variety of aetiologies for 
their hepatic failure. Their ages ranged from 15 to 60 
years with a median of 37 years and there were 5 males and 
13 females. 8 survived the episode of acute liver failure 
(44%). 9 developed fulminant hepatic failure of whom 1 
survived (11%) . 2 of these patients has a sub-acute form of 
hepatic failure with a prolonged period of over 8 weeks 
before they deteriorated neurologically and even then they 
did not reach grade IV coma. Three of the patients were
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treated with a liver transplant 2 of whom survived. One 
further patient died on the list awaiting transplantation.
The comparison of prognostic factors between the survivors
and non survivors is shown in table 3.
Table 3 survivors non survivors signif.
age 40 (31-66) 35 (15-60) N.S.
sex F/M 7/1 F/M 6/4 -
admission 
coma grade 2 (1-4) 2 (1-4) N.S.
AST 502 (225-1384) 2580 (61-18000) N.S.
bilirubin 233 (96-302) 312 (108-607) N.S.
H+conc. 58 -
PT ratio 2 (1-2.5) 3.25 (1.5-5) N.S.
WBC 24 (5-25) 11 (1.6-49) N.S.
creatinine 100 (59-296) 161 (53-792) N.S.
first 48 hrs 
coma grade 2 (1-4) 4 (1-4) N.S.
AST 363 (127-1384) 802 (62-18000) N.S.
bilirubin 134 (31-302) 34 (96-675) N'.S.
H+conc. 38 (28-50) N.S.
PT ratio 2.5 (1-5) 3.5 (1.8-5) N.S.
WBC 24 (5-25) 13 (2-52) N.S.
creatinine 213 (59-450) 186 (66-819) N.S.
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The different aetiological groups are compared in table 4
Table 4 paracetamol viral others
age 27 (14-56) 35 (1.5-60) 37 (15-66)
sex M/F 12/36 8/15 5/13
% developing FHF 42% 47% 50%
overall survival 65% 43% 44%
survival in FHF 25% 36% 11%
% transplanted 2% 74% 17%
% transplant survival 0% 47% 67%
time from onset of symptoms
till admission (days) 3 (1-5) 14 (7-90) 14 '(2-100)
prognostic factors effective 
at predicting outcome YES NO NO
Discussion
From these results it is seen that acute hepatic failure, 
particularly in its fulminant form, is a disease associated 
with a considerable mortality. Despite the improvements in 
this situation predicted a few years ago (Buckets 1987, 
Bismuth 1987) with the introduction of liver 
transplantation as a treatment for this condition the 
longer term results have not been as good as anticipated. 
Reasons for this include donor shortage and the short time 
interval during which liver transplantation can be 
undertaken.
A better understanding of the natural history of fulminant 
liver failure must be achieved so that those patients who
25
will benefit from transplantation can be identified early 
and selected for this mode of therapy and the others who 
can be managed by conventional medical therapy do not use 
up the restricted number of donor organs or have to undergo 
unnecessarily the future disadvantages of a life of 
immunosuppressive therapy.
Several hepatologists have assessed prognostic factors in 
order to identify the group of patients likely to do worst 
with conservative management and so indicate those who 
should be offered transplantation. However, our results 
show that these parameters of degree of acidosis, 
prothrombin ratio, white cell count, transaminase or 
bilirubin levels, coma grade or creatinine level are only 
applicable to the patients who took paracetamol overdoses 
and that they do not predict the patients who will do badly 
with viral hepatitis or from the other assorted hepatitis 
aetiologies. In understanding other series assessing 
prognostic factors the relative proportions of the various 
aetiologies must be known since the size of the paracetamol 
group will distort the findings.
The viral group contained a higher proportion of patients 
who underwent liver transplantation and the direct 
consequences of this therapy may have altered the 
predictive accuracy of the prognostic factors; to the 
extent that survival in this group might reflect the 
ability to overcome the transplantation procedure rather 
than the natural history of the disease.
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The results from this study indicate that for patients who 
have liver damage due to the ingestion of paracetamol the 
admission severity of hepatic coma, prothrombin ratio, 
bilirubin, hydrogen ion and creatinine levels are adequate 
to identify those who are unlikely to survive with 
conservative therapy alone.
Whole or partial organ transplantation cannot be the best 
answer to the treatment of liver failure in all patients.
It is a considerable trauma to an already seriously ill 
patient and commits him or her to a life time of 
immunosuppression and all of its associated problems. Even 
if the liver is successfully transplanted and functions 
satisfactorily there is sometimes no return of neurological 
activity as happened in 3 of our patients, one in the 
paracetamol group and 2 in the viral group. Organ 
transplantation is not applicable to the patient with 
psychological or emotional imbalance and should only be 
considered in a small number of the instances of 
paracetamol overdose.
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Comment
These findings prompted an investigation into providing a 
temporary method of liver support using cellular material 
and subcellular substances in an experimental model of 
acute hepatic failure to try to determine a short term, 
readily available, hopefully easily administered treatment 
which would improve survival and be adaptable to fit the 
clinical needs in fulminant hepatic failure.
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TREATMENTS OF ACUTE HEPATIC FAILURE - PAST AND PRESENT
Diseases attributable in origin to the liver were 
recognized early in medical history (5th and 4th centuries 
B.C.) but since no diagnostic investigations were possible 
treatments were to say the least empirical, entailing 
various ways of draining abscesses and at about 300-250B.C. 
Erasistratos is reported as opening the abdomen and 
applying medication directly to a diseased liver. At this 
time paracentesis through the umbilicus was employed to 
remove ascites.
Major changes in therapy did not develop until the 19th 
century when, with the aid of the microscope, it was 
possible to differentiate different types of liver disease. 
A diagnosis of hepatitis could be made but the clinicians 
of that day considered it to be stage in the development of 
a liver abscess. Liver congestion was similarly thought to 
be a forerunner of hepatitis. Treatment for this sequence 
of diseases was based upon blood-letting particularly by 
English physicians such as Annesley, Twining and Morehead 
working in tropical countries. In 1887 however the German 
pathologist Thierfelder stated that he was unable to show 
any direct effect of blood-letting on the inflammatory 
process. A more direct approach was instituted by MacLean 
and Harley who plunged a trocar 15cm into the liver to 
drain pus and/or blood. Despite the exponents' enthusiastic 
reporting of the healing produced, this therapy was not 
generally accepted. Other treatments used at this time
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included emetics and purgatives, calomel, nitric acid, 
mercury, blistering plasters, mustard fermentations and 
iodine compounds. This "hepatitis" is unlikely to be the 
pathological entity that is now recognized by that name.
Outbreaks of endemic jaundice were encountered in the 17th, 
18th and 19th centuries and these may have been similar to 
some of the infective types of hepatitis diagnosed today. 
The treatment of this disease was mainly by purgatives and 
dietary measures and often no therapy was given since it 
was observed that "for the most part this endemic hepatitis 
cured itself spontaneously".(reported by Franken, 1974)
Fulminant hepatic failure was first described by Lucke and 
Mallory in 1946 as severe, acute impairment of hepatic 
function culminating in hepatic encephalopathy. This was 
modified in 1970 by Trey and Davidson who stated that the 
encephalopathy must develop within 8 weeks of the onset of 
the illness in a person with no evidence of previous liver 
disease. This definition excludes a group of patients in 
whom the long term sequel and survival are in many ways 
similar to the group with acute fulminant hepatic failure 
but in whom the development of encephalopathy takes longer 
to manifest itself. This more protracted form has received 
a variety of names including late onset hepatic failure, 
subacute or subchronic atrophy of the liver, subacute 
hepatitis, subacute (fatal) hepatitis and subacute hepatic 
necrosis. Most of these cases are thought to be viral in 
aetiology, have similar symptoms and signs to the more
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familiar acute form but to have a higher proportion of 
older patients in the series.
General Supportive Measures
The mainstay of treatment of acute fulminant hepatic 
failure is by general supportive measures, paying attention 
to fluid balance usually with central venous pressure 
monitoring and closely observing urine volumes with 
recourse to renal stimulation with drugs such as frusemide 
or dopamine if necessary and early resort to dialysis 
either peritoneal or haemodialysis if indicated. 
Hypoglycaemia must be detected and treated by continuous 
dextrose infusions, often in increasing concentration as 
the patient's condition dictates. Biochemical monitoring of 
electrolyte concentrations and acid base balance is 
essential with correction of parameters to physiological 
levels. Reduction in liver produced coagulation factors 
leads to a prolonged prothrombin time making the patient 
susceptible to haemorrhage and fresh frozen plasma is 
administered when there is a danger of bleeding. As the 
level of hepatic coma increases the patient is unable to 
protect his own airway and endotracheal intubation often 
with mechanical ventilation is needed.
The onset of seizures is a serious complication associated 
with raised intracranial pressure and the presence of 
increased pressure can be detected and treated immediately 
by monitoring the intracranial pressure by placing a probe 
into one of the lateral ventricles. Treatment involves the 
administration of mannitol or other diuretics, ensuring a
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high ventilatory pressure and nursing the patient in a head 
elevated position.
With increasing intensive care facilities the application 
of these measures has improved the survival prospects of 
patients with acute fulminant hepatic failure in the last 
20 years. While in the 1960's the reported mortality was 
95% (Gazzard 1974) now in the late 1980's the survival rate 
of patients reaching grade 4 coma has only reached 20% 
(Christensen 1984). Mortality rates vary depending on the 
underlying aetiology of the hepatic failure; patients with 
hepatitis A, hepatitis B and paracetamol overdose doing 
significantly better than people with non A non B hepatitis 
or drug reactions. Survival rates quoted in different 
studies are dependant on the relative proportions of the 
principle aetiologies and the age distribution of the 
patients studied.
Corticosteroids
Steroid therapy has gone through phases of popularity since 
it was first advocated by Ducci and Katz in 1952/ being 
considered beneficial in viral hepatitis and in reducing 
cerebral oedema. This was countered by the increased 
incidence of gastric erosions and susceptibility to * 
infections. The first randomised trials of steroid therapy 
(Ware et al 1974, Redeker et al 1976, Gregory et al 1976) 
failed to show any benefit but were criticised because of 
the small numbers of patients studied. In the multicentre 
trial instituted by the European Association for the Study 
of the Liver there was no difference in survival or side
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effects of therapy between the steroid group and the 
controls although the number of patients included in the 
study was still only 40 and the aetiologies were not 
similar in each group.
Charcoal haemoperfusion
Gazzard et al in 1974 reported spectacular success using 
charcoal haemoperfusion in patients with grade 4 coma; a 
50% recovery rate and 45% ultimate survival rate. They 
compared these results to their previously published series 
of patients who received the same supportive treatment but 
no charcoal haemoperfusion with a survival rate of 10%. The 
distribution of aetiologies was said to be similar but the 
number of patients studied was small. The same group then 
extended this therapy to those patients in grade 3 coma 
(Gimson, 1982) in a more strict regime with prostacycline 
infusion as platelet protection. Daily haemoperfusion, 
started when the patient was in grade 3 coma, achieved a 
survival rate of 65% compared to a 20% survival rate if the 
haemoperfusion was started in grade 4 coma. All the grade 3 
patients did deteriorate into grade 4 so the severity of 
liver failure was comparable in both groups. There was less 
cerebral oedema in the group treated earlier; 49% compared 
with 78% in the group treated later. Despite the authors' 
concluding comment that a randomised control trial of this 
therapy against intensive supportive therapy would be 
difficult to justify ethically, they did proceed to this.
In 1988 O'Grady et al published the results of two trials 
of charcoal haemoperfusion therapy. Different durations of
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haemoperfusion were compared in grade 3 patients and no 
difference was seen in the survival or cerebral oedema 
results between the two groups. In grade 4 coma patients 
charcoal haemoperfusion was compared in a randomised study 
with conventional therapy and no difference was found.
There were slightly more patients from the aetiological 
groups with poorer prognoses in the control group but not a 
large enough difference to be significant. Even in this 
trial numbers were still insufficient to demonstrate small 
changes in survival rates; 29 patients in the treatment 
group and 33 in the control group.
As an alternative to charcoal the same group from King's 
College Hospital employed a mesh of XAD-2 resin in the 
haemoperfusion columns as a way of removing protein bound 
toxins from the circulation of experimental animals with 
ischemia-induced acute hepatic failure. (Weston et al 1974) 
This was technically unsuccessful because of haemorrhagic 
problems due to platelet adherence to the resin producing 
thrombocytopenia in the animals.
Large pore membrane haemodialysis
Haemodialysis can not only be used to substitute deficient 
renal function in patients with acute hepatic failure but 
also to filter out of the circulation some of the 
substances normally metabolised by the liver. To do this 
the usual haemodialysis membrane must be substituted for 
one with a larger pore size. Silk et al (1977) used a 
polyacrylonitrile membrane in a conventional haemodiaysis 
set-up as part of the treatment of 24 patients with
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fulminant hepatic failure who had reached grade 4 coma.
They concluded that their survival figure of 33% was 
similar to that they obtained during their phase of 
enthusiasm for charcoal haemoperfusion and better than that 
for conservative therapy. Their results were not supported 
by the study performed by Denis et al (1978) who failed to 
show any difference in survival over conservative 
management, although they achieved an increased occurrence 
of the return to consciousness.
In 1983 de Groot again employed this large pore membrane in 
haemodialysis in pigs with ischemically induced acute 
hepatic failure and found a significant improvement in 
survival compared to a control group which did not receive 
haemodialysis. In this study one period of 6 hours of 
dialysis appeared to be sufficient to improve the survival 
but all animals eventually died because the dialysis was 
unable to support the animal indefinitely in this model of 
irreversible acute liver failure.
Exchange transfusion
Other methods have been used to try to remove toxic 
substances from the circulation. In 1967 Jones et al 
employed exchange transfusion of blood to try to wash out 
harmful particles in seven patients with hepatic failure; 
six in grade 4 coma at the start of the treatment and one 
in grade 3. Despite the transfusion of between 5 and 58 
litres of fresh blood per patient all died of liver failure 
with other complications directly attributable to the 
therapy. This study was in contrast to previously published
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work giving encouraging results for this treatment. (Trey 
1966, Berger 1966) . All these reports had a small number of 
patients (one in the paper from Berger), the ages of 
patients were different between the groups and so were the 
predominant aetiologies and severities of the liver 
failure.
Cross circulation
In the early 1970's when mechanical means of liver support 
were unsuccessful the procedure of cross circulation was 
tried allowing the blood from the patient with hepatic 
failure to circulate through the body of another human in 
the hope that the "donor's" liver would perform the 
functions that of the patient was unable to do. (Burnell 
1973) Donors used included patients with widespread 
malignancy, chronic renal failure and in one case thé 
healthy son of the hepatic failure patient. Survival of the 
patients was in the region of 20% so it contributed nothing 
more than conservative treatment and not only did most of 
the donors develop some morbidity from the procedure but 2 
died of causes directly attributable to the technique.
Cross circulation was also used connecting the human 
patient to animals such as baboons (Bosman 1968).
Extracorporeal liver perfusion
This approach of perfusing through whole people or animals 
was modified by the removal of a donor liver from the body 
and setting up an extracorporeal liver perfusion with the 
blood of the patient circulating through the isolated 
liver. Various animals have been used in this way for the
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treatment of humans and Abouna (1970) reported a case in 
which one patient with hepatic failure underwent a series 
of 16 extracorporeal liver perfusions employing the livers 
of 10 pigs, 3 baboons, 1 calf, 1 monkey and 1 human as well 
as 20 exchange blood transfusions. Although there were 
temporary improvements in the patient's condition there was 
no return of liver function and the patient died after 76 
days of this treatment. Human livers obtained from cadavers 
were found to be better than livers from other species 
since they functioned for longer (Abouna 1970, Sen 1966) .
Liver transplantation
A logical progression from this treatment has been the 
placement of the donor liver inside the patient with 
fulminant hepatic failure. Since 1984 increasing numbers of 
liver transplant centres have reported their experience of 
orthotopic liver transplantation in the treatment of acute 
hepatic failure.(Williams 1984, Adams 1986, Ringe 1986, 
Buckels 1987, Bismuth 1987, Brems 1987, Peleman 1987, 
Vickers 1988). This mode of therapy has run parallel to the 
improved results of liver transplantation for chronic liver 
diseases. This form of treatment for selected patients in 
grade 4 hepatic coma produces survival rates of 55%-74%.
The differences in the results of all the quoted studies 
are dependant upon the ages of the recipients and the 
neurological status of the patients before transplantation. 
Early reports dealt only with a few patients but now 
results are available for larger series.
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Liver transplantation is unfortunately not an option 
available to all patients developing fulminant liver 
failure. A small number will recover spontaneously with 
conservative medical management and for them 
transplantation is not needed and would be detrimental. A 
few patients will have developed irreversible neurological 
damage by the time of referral to a transplant centre and 
for them liver replacement would be a waste of resources. 
Moral decisions are required to justify transplantation of 
selected patients with paracetamol overdose liver failure, 
since some of these people will proceed to take further 
overdoses (Burglass 1974, Goldacre 1985) . Viral hepatitis 
(hepatitis B, delta hepatitis and some forms of non A non B 
hepatitis) can recur in the new liver (Rizetto 1987, Ferla 
1988) and most patients who are positive for hepatitis B 
antigen retain this antigenicity after transplantation.
In an attempt to reduce the long term morbidity associated 
with orthotopic transplantation, heterotopic (auxiliary) 
liver transplantation appears a sensible therapeutic option 
in acute liver failure. The insertion of a second liver 
below the native one to supplement its function while it 
recovers from the temporary failure, and then removal of 
the donor liver once the original organ is again 
functioning satisfactorily would have obvious advantages. 
This would involve only a limited period of 
immunosuppressive therapy. To date results of heterotopic 
liver transplantation in acute hepatic failure have not 
been very successful (Diaz 1977) and with 1 out of 3 
surviving in the series reported by Terpstra (1989).
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Comment
Despite the recent advances in the treatment of acute 
hepatic failure particularly in relation to liver 
transplantation survival figures, though improved, are not 
universally attainable for all sufferers with this disease 
Death still occurs due to cerebral oedema in a substantial 
number of patients and although therapies such as charcoal 
haemoperfusion reduce the duration of hepatic coma they do 
not prevent a fatal outcome. The therapy of liver 
transplantation has produced major advances for selected 
patients but it means major surgery in a critically ill 
individual and commits the patient to life long 
immunosuppression. Some of the initial mortality and 
subsequent morbidity might be reduced if isolated 
hepatocytes or hepatocyte derived substances could be 
administered as temporary support.
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EXPERIMENTAL HEPATOCELLULAR TRANSPLANTATION
Hepatocyte transplantation was first reported by Rugstad in 
1970 when he implanted cells from a rat hepatoma into the 
subcutaneous tissues of a Gunn rat. The Gunn strain is 
deficient in the enzyme bilirubin uridyldiphosphate 
glucuronyl transferase and therefore has an unconjugated 
hyperbilirubinaemia (Gunn 1938). Following transplantation 
the rats were capable of conjugating bilirubin and the 
serum levels fell. Obviously the transplantation of 
neoplastic tissue did not hold much clinical application 
and so in 19 73 Mukherjee placed fragments of normal liver 
from a Wistar rat into the liver of a Gunn rat and also 
achieved a reduction in serum bilirubin.
Isolated hepatocytes grown in cell culture had been shown 
to be metabolically active and so Matas and Sutherland 
(1976) infused a hepatocyte suspension from a Wistar rat 
into the portal vein of a Gunn rat and demonstrated that 
the bilirubin fell. However when the cells were placed 
intraperitoneally a drop in bilirubin level was not 
observed, neither was a positive result obtained when cells 
from other organs e.g. spleen were injected into the portal 
circulation. These findings were confirmed by other workers 
(Groth 1977). The intramuscular route also proved 
unsuccessful for hepatocyte function. The transplanted 
cells were identifiable in the portal vein branches within 
the liver in the early post transplant period but they 
became less easy to locate later in the study. Various 
explanations were suggested for these results; including
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bilirubin conjugation having occurred within the donor 
hepatocytes, the possibility that the infused cellular 
material blocked up the reticuloendothelial system and 
delayed the breakdown of old red blood cells with reduced 
bilirubin synthesis being responsible for the lower serum 
levels (Woods 1981). He supported this latter theory by 
demonstrating that splenectomy reduced the serum bilirubin 
level in the Gunn rat. Vroemen in 1985 showed by using an 
allogeneic rat model that it was in fact the transplanted 
cells that produced the missing enzyme because the 
bilirubin level fell initially but after rejection and loss 
of the hepatocytes and bilirubin returned to pretransplant 
levels. Hepatocyte transplantation was then tried for 
different enzyme deficiencies in the experimental rat 
(Demetriou 1986a, Kebukuro 1987) .
Since allogeneic hepatocytes are immunologically rejected 
(Ebata 1985) when non syngeneic cells are transplanted 
immunosuppression needs to be given to ensure donor cell 
survival (Makowka 1986, Darby 1986, Cobourn 1987).
In 1977 Sutherland showed that the mortality of rats with 
hepatotoxin induced hepatic failure could be reduced from 
80% to 30% by hepatocellular transplantation. This was 
initially thought to be due to the transplanted cells 
taking over the hepatic function until the native liver 
regenerated, but on histological examination it was 
difficult to see new cells in the liver when they had been 
injected intraportally and no evidence of viable cells was 
found in the peritoneal cavity in the rats which received
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the cells intraperitoneally. Sommer (1979) confirmed these 
observations in a model using a different hepatotoxin. He 
also transplanted hepatocytes into the spleen where they 
appeared to survive with an increase in animal survival 
from 20% to 70%. When this therapy was applied to rats with 
a 70% hepatectomy there was also improved survival (Minato
1984). Different groups of workers have found this 
technique effective if the cells are given at certain 
restricted time periods after the induction of acute 
hepatic failure (Makowka 1980a, Cuervas-Mons 1984) but the 
differences are probably related to the different 
hepatotoxins involved, doses of hepatotoxin or volume and 
concentration of hepatocyte suspensions and to the 
different strains of rats used. All of these variables make 
comparison of the results difficult.
Makowka (1980a,b,c) showed that allogeneic hepatocytes were 
effective at reducing the mortality as were xenogeneic 
cells (pig or rabbit hepatocytes transplanted into rats).
If the cells were given intraperitoneally there was also an 
improvement in survival but no functioning hepatocytes 
could be detected histologically in the peritoneal cavity. 
Irradiated hepatocytes which could not divide (Kawai 1987) 
and cryopreserved hepatic cells with a limited life (Kusano 
1981) were also able to reduce the mortality rates of rats 
with acute hepatic failure. Radiolabelling of the donor 
hepatocytes showed that the transplanted cells were not 
repopulating the native liver.
These experiments made it difficult to believe that 
intact, metabolically active hepatocytes were responsible
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for the improvements in survival. It was postulated that 
the cells could be producing or releasing a substance that 
was increasing the rate of regeneration of the surviving 
native hepatocytes. Makowka (1981) demonstrated that 
cytosol prepared from the liver of a rat that had undergone 
a substantial hepatectomy was capable of producing the same 
results as isolated hepatocytes when injected 
intraperitoneally. Similar results were obtained when 
cytosol from fetal or weanling liver was used but cytosol 
from normal adult rats liver was not effective in reducing 
the mortality from acute hepatic failure. Cell-free 
supernatant from hepatocyte cell culture was administered 
in a similar way and also proved effective therapy in the 
rat (LaPlante O'Neill 1982) as did implantation of cells 
from other tissues e.g. bone marrow cells (Makowka 1980c).
Therefore although intact functioning hepatocytes appeared 
to be needed to produce a substitute liver in the enzyme 
deficient rat, the mode of action of the transplanted 
hepatocytes in the acute liver failure experiments did not 
appear to be dependant on cellular function.
Various sites of implantation have been tried in each 
experimental group; ranging from liver (Sutherland 1977), 
which makes identification of the donor cells very 
difficult, spleen which appears to be the most suitable 
environment (Mito 1979), pancreas (Vroemen 1988b, Jaffe 
1988), under the capsule of the kidney (Ricordi 1988), the 
peritoneal cavity (Sutherland 1977),, the dorsal
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subcutaneous fat pad (Jirtle 1982), muscle (Groth 1977) and 
the lung (Selden 1984).
Long term experiments have shown healthy looking 
hepatocytes present in the spleen more than a year after 
transplantation. By this time they have settled into an 
orientation which looks identical to liver parenchyma with 
the establishment of columns of hepatocytes with sinusoidal 
spaces detected between (Maganto 1988) . These hepatocytes 
can be seen to account for up to 40% of the spleen, 
suggesting cellular replication. On electron microscopy 
bile canalicula, desmosomes between the cells and the 
appearance of endothelial cells lining the sinusoids can be 
detected. The intracellular organelles appear to be the 
same as those in non transplanted hepatocytes.
Vroemen(1988a) showed that the transplanted hepatocytes in 
the spleen showed mitotic activity and cellular 
proliferation throughout the first 20 weeks after 
transplantation not as a late phenomenon as was initially 
believed following the work of Kasano and Mito (1982). Most 
workers have failed to show definite evidence of cell 
proliferation in these hepatisized spleens (Cuervas-Mons
1985) and to date the mechanism of hepatic establishment is 
purely speculative but may be controlled by "trophic" 
factors.
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Cryopreservation studies have enabled isolated hepatocytes 
to be stored in a frozen state at -196°C and then function 
after thawing and transplantation into the spleen of 
syngeneic rats (Maganto 1986).
Demetriou (1986a,b) has developed a method of attaching 
isolated hepatocytes to collagen coated microcarriers which 
can then be injected intraperitoneally into experimental 
rats. These microcarrier-attached hepatocytes were also 
functional when transplanted after 2 weeks storage at 
-80°C.
Hepatocytes have also been encapsulated in alginate 
microspheres prior to transplantation to reduce the 
antigenic stimulus when injected into allogeneic animals 
and these encapsulated groups of cells appear to function 
similarly to isolated hepatocytes (Wong 1986, Sun 1986) .
Comments
Hepatocellular transplantation has now developed to the 
stage when groups of isolated hepatocytes can successfully 
be injected into experimental animals with long term 
survival of the cells and good cellular function even to 
the extent of the development of ectopic hepatic tissue 
within the recipient spleen. The cells can be adapted for 
storage and their immunogenicity modified to allow timing 
and interspecies flexibility of use.
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MATERIALS AND METHODS
RATS
All the rats used except one in the cell culture 
experiment, which was female, were adult male Wistar rats 
obtained from the breeding colony in the Department of 
Biochemistry, University of Birmingham. They had free 
access to standard laboratory rat chow and water throughout 
the experiments and were maintained in the Department of 
Surgery Animal House in a room at a constant temperature 
and exposed to normal diurnal variation in light.
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RAT HEPATOCYTE ISOLATION 
Apparatus
A perfusion platform was mounted on the edge of a water 
bath which was heated to maintain the water at a ’constant 
temperature of 37°C. In the water bath were placed the 
following which were connected in order by means of plastic 
tubes; (i) a glass reservoir for the perfusion solution 
which could be filled via a funnel inserted in its neck and 
which emptied by gravity via a spout in its base. It also 
had 2 entry spouts near the neck to facilitate 
recirculation. Tubing from the reservoir exit was connected 
to the input spout of (ii) a bubble trap, to prevent air 
bubbles entering the system. The tubing from here passed 
out of the water bath and through a rotating pump head, the 
speed of which could be varied to produce different flow 
rates and then back into the water bath where it was
connected to (iii) a heat exchange coil, the outflow from
which could be attached to a cannula for tissue perfusion. 
The perfusion platform drainage channel could be connected 
by tubing to one of the input spouts of the reservoir.
Solutions
(a) Hank's balanced salt solution (HESS) without calcium or 
magnesium with phenol red (Sigma) reconstituted from powder 
with addition of sodium bicarbonate as directed by the 
suppliers and adjustment of the pH to 7.44 immediately 
prior to use.
(b) Collagenase solution. 50 mg of collagenase H
(Boehringer Mannheim) was added to 100 ml of HESS (sol. a)
to which was also added 1.5 ml 500mM calcium chloride.
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(c) Hank's balanced salt solution with calcium and 
magnesium (HBSS+) (Sigma) which was reconstituted with the 
addition of sodium bicarbonate according to the suppliers 
instructions and the pH adjusted to 7.44 immediately prior 
to use.
Procedure
The method used was a modification of that described by 
Seglen (1976) which was based on the initial work by*Berry 
and Friend (1969). Perfusion was performed without 
oxygenation or the addition of a biological buffer, but 
with intermittent addition of sodium hydroxide to the 
outflow from the liver before return to the reservoir 
during the collagenase perfusion phase.
The rat was anaesthetised with an intraperitoneal injection 
of pentabarbitone at a dose of 60 mg/kg and placed supine 
on the perfusion platform. A bilateral subcostal incision 
with sternal extension was made and the gastrointestinal 
tract reflected to the animal's left. The infrahepatic 
inferior vena cava (IVC) was encircled with silk ties and 
the IVC cannulated with an 18G cannula which was secured in 
position with the ties. 200 units of heparin was 
immediately injected via the cannula. The portal vein was 
divided and the intrathoracic IVC was ligated. The 
perfusion tubing was then connected to the cannula and 
perfusion commenced with 500 ml of HBSS at a flow rate of 
28 ml/min. This flow rate was maintained throughout. 
Following this the liver was perfused with collagenase 
solution which was recirculated with correction of the pH
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as necessary with sodium hydroxide. The collagenase 
perfusion was continued for about 10 minutes, the duration 
assessed by the appearance of the liver. When the liver 
looked digested the pump was stopped and the liver removed 
from the animal and placed in a tray containing HBSS+. The 
capsule was incised and the liver raked with forceps to 
release the hepatocytes from the vascular network. This 
crude cell suspension was passed through a double layer of 
gauze and then through a nylon mesh. The suspension was 
divided into centrifuge tubes and centrifuged at 300rpm for 
3 minutes. The supernatant was removed and discarded and 
the loose pellet of cells resuspended in HBSS+. The * 
centrifugation and resuspension was repeated twice and the 
volume of the resultant suspension adjusted to a manageable 
amount. Cell viability was assessed by Trypan blue 
exclusion and a total cell count made after suitable 
dilution of a sample of the suspension. (Figs. 1-12)
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Fig. 1. Apparatus.
Fig. 2. Rat on perfusion platform.
Fig. 3. Normal liver exposed
Fig. 4. Cannula inserted into inferior vena cava.
Fig. 5. Liver perfused with HESS
Fig. 6. Liver perfused with HESS, view of porta hepatis
Fig. 7. Perfusion with HESS.
Fig. 8. Recirculating perfusion with collagenase soln
Fig. 9. Collagenase perfusion
/>
Fig. 10. Liver after removal
Fig. 11. Hepatocyte suspension prior to centrifugation
Fig. 12. Hepatocytes during centifugation and resuspension
Trypan blue exclusion
0.1 ml 0,4% Trypan blue (Sigma) was mixed with diluted cell 
suspension (usually 0.1ml cells with 0.8 ml HBSS+) to give 
a final cell dilution of 1 in 10. This was instilled into a 
cell counting chamber and viewed under a microscope. The 
number of cells taking up the dye was counted, as was the 
total number of cells within the same area. The viability 
was calculated from the total cells minus the blue ones, 
divided by the total number and the result expressed as a 
percentage.
Total cell count
The total number of cells in the prescribed area of the 
counting chamber was adjusted for the dilution and the 
volume of the chamber to give the number of cells per ml of 
the suspension. This could be multiplied by the total 
volume to determine the yield from the liver.
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PREPARATION OF CYTOSOL
Cytosol was prepared from a suspension of isolated 
hepatocytes which was produced as described before. After 
centrifugation and washing of the cells the suspension was 
subjected to ultrasound bombardment in the Soniprep at 
power setting of 14 for 5 minutes to break down the cell 
structure. (Fig. 13) The resultant mulch was 
ultracentrifuged at 40,000 rpm for 90 minutes and the 
supernatant removed. This solution of intracellular 
substances was filter sterilised, divided into individual 
doses and frozen at -20^C till required. Immediately prior 
to use it was thawed at 37°c. Dosages were calculated 
according to the number of hepatocytes used in the 
preparation.
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Fig. 13. Cells disrupted in Soniprep, prior to spinning in 
ultracentrifuge.
COAGULATION AND BIOCHEMICAL MONITORING
Monitoring of the animals' progress to recovery or death 
was by the measurement of "Normotest" (Nycomed Diagnostics) 
to determine the activity of coagulation factors II, VII 
and X. The test reagent was reconstituted according to the 
supplier's instructions by adding 11ml sterile distilled 
water to the contents of the ampoule. This solution was 
divided amongst small tubes each containing 0.25ml of 
reconstituted reagent solution. These were stored at -20°C 
and heated in a water bath at 37°C for 10 minutes prior to 
use. Blood was obtained from the rat and 0.1ml of blood was 
placed in a tube containing 0.01ml of 0.109M trisodium 
citrate. 0.025ml of this citrated blood was pipeted into 
the reagent and the time taken for coagulation to occur in 
a water bath at 37^C was noted. This Normotest time in 
seconds was then plotted on the correlation curve supplied 
by the company to calculate the Normotest percentage.
Biochemical liver function tests were measured on plasma 
obtained by centrifugation of fresh blood from the rat and 
the plasma stored at -20^0 till biochemical analysis was 
undertaken. Alanine aminotransferase was measured on a 
Cobas Bio centifugal analyser using Boehringer Mannheim 
reagent (product No.124524). Aspartate aminotransferase was 
measured on a Hitachi 737 fully selective analyzer with 
Boehringer Mannheim reagent using the "optimised standard 
method". Alkaline phosphatase was measured by the 
"optimised standard method" using Boehringer Mannheim
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reagents on the Hitachi 737 analyzer. Bilirubin was 
measured on the same analyser.
Biochemical analyses were performed by the staff of the 
Department of Clinical Chemistry, Queen Elizabeth Hospital
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STATISTICAL METHODS
In the clinical study the various results obtained did not 
fit the normal distribution and so these measurements were 
analysed nonparametrically with the medians and ranges 
being given.
Within each test group of rats the results for each 
modality tested appeared to conform to a normal pattern and 
so within the group the analysis was by parametric methods 
with means reported. However when comparing one group with 
another the analysis was by nonparametric methods.
Statistical analyses were performed by computer using the 
"Statgraphics" software package (STSC, Inc. USA.)
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ACUTE HEPATIC FAILURE MODEL
For the purposes of the study it was necessary to develop a 
reproducible model of acute hepatic failure in a small 
animal so that different treatment options could be tried. 
The administration of a known hepatotoxic agent was the 
most convenient available method and so dimethylnitrosamine 
was chosen as the hepatotoxin.
Dimethylnitrosamine (DMNA) is a liver specific toxic agent 
having its effect on the hepatocyte by alkylation of the 
molecules of the nucleus and the cytoplasm and hence by 
means of a metabolic injury producing tissue necrosis. 
Histologically DMNA produces a zonal necrosis of the 
centrilobular type (zone 3) similar to the pattern 
encountered in clinical practice following ingestion of 
hepatotoxic agents such as paracetamol. (Zimmerman 1987)
DMNA was implicated as a hepatotoxin in 1954 by Barnes and 
Magee who in a series of experiments in different species 
produced both acute and chronic liver injury by using 
different doses of the substance over different time 
schedules. They showed that acute hepatic failure could be 
produced in albino rats by a single intraperitoneal 
injection or by one oral dose. The results of oral 
administration were less dependable and less reproducible 
than if the substance was given intraperitoneally. In the 
rats they used the L.D. 50 by intraperitoneal injection was 
26.5mg/kg. and the average oral dose to produce the same 
effect was 40 to 50mg/kg. The rats died between 2 and 5
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days after administration of DMNA. Magee (1956) 
demonstrated that DMNA is rapidly metabolised and that 4 
hours after dosage to the rat none was recoverable from the 
animal's body.
Adult male Wistar rats were chosen as the experimental 
animals and it was decided to administer the hepatotoxin in 
a single intraperitoneal injection.
The doses of DMNA originally chosen for testing in this 
strain of rat were 40mg/kg and 50mg/kg and following the 
results of these doses 45mg/kg was also given.
There were 3 rats in each test group all weighing between 
300 and 390g.
All rats were anaesthetised with ether and a blood sample 
was taken from the tail vein of each for coagulation 
testing with "normotest" and biochemical liver assessment 
measuring alanine transaminase (ALT), aspartate 
transaminase (AST), alkaline phosphatase (AP) and bilirubin 
(Bil). The volume removed (0.2ml) was replaced with saline 
intravenously. While still anaesthetised each rat was 
injected intraperitoneally with DMNA, Ig of which had been 
diluted with 50ml of normal saline to produce a 
concentration of 20mg/ml. Dosages of 40mg/kg, 45mg/kg and 
50mg/kg were administered. The rats were allowed to 
recover, their physical states were observed, and blood 
samples, with volume replacement were taken regularly under 
ether anaesthesia for the same investigations as before.
All rats surviving the episode of acute liver failure were
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sacrificed when they appeared well. Postmortem examination 
was performed on all animals at death or sacrifice with 
removal of the liver for histological assessment of the 
degree of liver necrosis
Results.
All animals appeared unwell, becoming inactive, slow to 
respond and puffed out their coats.
Of the rats receiving 40mg/kg 1 died at 48 hour after the 
administration of DMNA while under anaesthesia and the 
other 2 survived with signs of full recovery to be 
sacrificed at 192 and 316 hours. All the rats given 50mg/kg 
died at 48 hours having been in a very poor physical state 
for the preceding few hours. One rat given 45mg/kg died at 
122 hours and the other 2 showed signs of recovery and were 
sacrificed at 151 hours.
Normotest (mean)
hours 0 6 16 24 48 72 96 120 144 sac.
dose
40mg/kg 45% 38% 21% 12% 31% 41% 33% 34% 45%
50mg/kg 50% 20% 4%
45mg/kg 44% 12% 4% 4% 39% 47% 52%
ALT (mean)
hours 0 6 16 24 48
dose
40mg/kg 101 61 94 1463
50mg/kg 54 ' 199 1064
45mg/kg 57 1189 252
hours 72 96 120 144 sac.
dose
40mg/kg 934 392 184 97 65
50mg/kg
45mg/kg 197 77 50
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AST (mean)
hours 0 6 16 24 48
dose
40mg/kg 225 128 300 5402
50mg/kg 144 605 2628
45mg/kg 106 2047 293
hours 72 96 120 144 sac
dose
40mg/kg 1710 676 323 267 100
50mg/kg
45mg/kg 283 134 127
AP (mean)
hours 0 6 16 24 48
dose
40mg/kg 396 432 442 508
50mg/kg 406 326 448
45mg/kg 393 381 884
hours 72 96 120 144 sac
dose
40mg/kg 696 803 723 667 536
50mg/kg
45mg/kg 664 587 519
Bil (mean)
hours 0 6 16 24 48 72 96 120 144 sac
dose
40mg/kg 10 10 10 10 10 10 10 10 10
50mg/kg 10 10 40
45mg/kg 10 10 10 10 10 10
Histology of the livers removed at postmortem showed 81% 
liver necrosis in the centre of a lobe in the rat which 
died at 48 hours in the 40mg/kg group and no liver necrosis 
was evident in the rats which survived in this group. In 
the 50mg/kg group there was a mean of 93% liver necrosis 
(at 48 hours) and 49% liver necrosis in the rat which died 
in the 45mg/kg group, with the remaining rats in this group 
showing 0% necrosis at sacrifice.
From these results it was clear that a dose of 40mg/kg of 
DMNA was insufficient to produce reproducibly fatal acute 
hepatic failure in the Wistar rat. A dose of 50mg/kg
58
produced the necessary biochemical derangement to indicate 
significant liver damage but the rapidity of fatal outcome 
might preclude any demonstration of effectiveness for 
treatments of the liver failure. 45mg/kg was given in an 
attempt to find a suitable compromise dose but this too 
proved insufficient.
50mg/kg appeared to be the only workable dose to produce 
the necessary degree of hepatic failure so this dose of 
DMNA was given to a further 5 rats to validate the model, 
demonstrating its consistency.
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Validation of model
5 adult male Wistar rats weighing 400 to 450 g were 
anaesthetised with ether and blood samples were taken from 
their tail veins as before with intravenous volume 
replacement with saline. Each rat received an 
intraperitoneal injection of DMNA at a dose of 50mg/kg and 
was allowed to recover. Its physical state was observed and 
further blood samples were taken at intervals with volume 
replacement. Postmortem examinations were performed and the 
liver histology was assessed.
Results
All 5 rats became physically unwell and died, 1 at 41 hours 
after DMNA injection, 2 at 42 hours and 2 at 43 hours
Normotest (mean)
hours
dose
50mg/kg
0
44%
18
11%
24
5%
42
ALT (mean)
hours 0
dose
50mg/kg 56
18
1216
24
2679
42
828
AST (mean)
hours 0
dose
50mg/kg 97
18
1083
24
6985
42
9488
AP (mean) 
hours 
dose 
50mg/kg
0
246
18
480
24
184
42
529
60
Bil (mean)
hours 0 18 24 42
dose
50mg/kg 10 10 12 27
The livers removed at postmortem all showed hepatic injury 
with a mean of 89% liver necrosis. (Figs. 14,15)
During this and subsequent experiments the histological 
appearances of the livers at different times during the 
recovery from acute hepatic failure were observed. After 
the initial injury with hepatocyte necrosis the central 
parts of the lobule surrounding the central vein appeared 
to involute and "cave in" leaving a hole which then 
developed an endothelial lining becoming a dilated central 
vein. As the recovery phase progressed the vein returned to 
normal size. Regeneration of hepatocytes from the 
periportal areas extended to reduce the size of the central 
vein. In some case the recovered liver showed evidence of 
bridging fibrosis and in one instance a granuloma. (Figs. 
16-18)
DMNA 50mg/kg administered in a single intraperitoneal 
injection to the adult Wistar rat produces severe liver 
injury which was fatal in all the animals. Despite the 
short survival time it was decided to use this model of 
acute hepatic failure in the subsequent experiments.
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Fig. 14. Normal liver, (x 10)
Fig. 15. Acute hepatic failure due to 50mg/kg DMNA. (xlO)
Fig. 16. Resolving acute hepatic failure with central vein
involution. (xlO)
Fig. 17. Resolved acute hepatic failure with bridging 
fibrosis. (xlO)
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Fig. 18. Resolved acute hepatic failure with granuloma 
(x40)
HEPATOCYTE TRANSPLANTATION
Hepatocyte transplantation has been shown to be effective 
as a means of therapy in the rat with experimentally 
induced acute hepatic failure (Sutherland 1977), and so it 
was decided to assess its efficacy in the DMNA model in the 
Wistar rat as a modality with which to compare other 
treatments. Hepatocytes were prepared as described 
previously and administered into both the intrasplenic and 
the intraperitoneal sites.
INTRASPLENIC HEPATOCYTE TRANSPLANTATION 
Method
19 male adult Wistar rats were divided into 3 groups. Group 
I - induction of acute hepatic failure followed 6 hours 
later by intrasplenic injection of hepatocyte suspension; 
group II - induction of acute hepatic failure followed 6 
hours later by intrasplenic injection of Hank's solution 
(HBSS+); group III - intrasplenic injection of hepatocyte 
suspension without induction of acute hepatic failure.
Acute hepatic failure was induced by a single 
intraperitoneal injection of DMNA at a dose of 50mg/kg. In 
group I two rats received 2 .5x10  ^hepatocytes with 
viability of 90%, two received 2.0x10^ hepatocytes with 
viability of 80% and five received 3.15x10^ hepatocytes 
with viability of 74%. In group III five rats each received 
2.86x10^ hepatocytes with viability of 88%. All the 
hepatocyte suspensions were given in a volume of 1ml.
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The rats weighed 320 - 460g and were divided into 3 groups; 
group 1 - 9  rats, group II - 5 rats, group III - 5 rats. 
Acute hepatic failure was induced in groups I and II but 
not in group III. Six hours later in groups I and II and at 
time 0 in group III the rats were anaesthetised with an 
intraperitoneal injection of pentabarbitone and a small 
left subcostal incision was made. The spleen was delivered 
into the wound and the lower pole was injected via a 25 
gauge needle with hepatocyte suspension in groups I and 
III, and with HBSS+ in group II. Bleeding was stopped by 
pressing on the injection site with a bacteriology swab.
The splenic vein was not tied or clamped. The spleen was 
returned to the peritoneal cavity and the wound closed with 
an absorbable suture and the skin closed with a prolene 
suture. Blood samples were taken before induction of acute 
hepatic failure, before intrasplenic injection and at daily 
intervals afterwards. At death or sacrifice all animals 
underwent postmortem examination with removal of the liver 
and spleen for histological examination.
Results
The mean survival was 50 hours in group I, 39 hours in 
group II and indefinite in group III with all animals 
sacrificed between 164 and 356 hours. The difference in 
survival between groups I and II was not statistically 
significant when analysed by the Mann-Whitney test.
Normotest (mean)
hours 0 6 24 48 72
group
I 48% 29% 6% 4% 8
II
III
60%
41%
63% 12%
32% 57% 40
96 120 144 192 300
36% 59% 44% 50'
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ALT (mean)
hours 0 6 24 48 72-
group
I 90 84 4062 1172 3002
II 44 53 1415 6335
III 60 526 165 94
hours 120 144 192 300
group III 51 58 49 41
AST (mean)
hours 0 6 24 48 72
group
I 95 153 4098 7785 7143
II 169 208 1387 14150
III 104 874 324 267
hours 120 144 192 300
group III 111 151 132 94
AP (mean)
hours 0 6 24 48 72
group
I 405 196 650 616 894
II 391 212 306 584
III 386 476 377 229
hours 120 144 192 300
group III 315 410 358 398
Bil (mean)
hours 0 6 24 48 72 96 120 144 192
group
I 10 10 10 24 30
II 10 10 10 48
III 10 10 11 11 10 10 11
300
10
Histology
In group I the one rat which died 7 hours after induction 
of acute hepatic failure showed no histological evidence of 
liver necrosis but the other 8 all had liver destruction 
with a mean of 73% necrosis. In 8 of the spleens it was 
possible to identify groups of hepatocytes but these were 
small in number although the cells appeared viable. (Figs
64
19,20) In all the livers there were deposits of hepatocytes 
within some branches of the portal vein and in most cases 
these contained viable cells. (Fig. 21)
In group II the livers had a mean of 80% necrosis and no 
cellular deposits were seen in the portal vein branches.
The spleens all showed some haemorrhage from the injections 
but were otherwise normal.
In group III there was no evidence of liver necrosis and 
only 2 of the livers had any hepatocyte deposits within the 
portal vein branches but this was at a mean of 259 hours 
after transplantation. All the spleens in this group 
contained collections of hepatocytes but these were neither 
large nor numerous.
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Fig. 19. Normal spleen. (x40)
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Fig. 20. Hepatocytes in spleen. (x40)
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Fig. 21. Hepatocytes in portal vein after intrasplenic 
transplantation. (xlO)
INTRAPERITONEAL HEPATOCYTE TRANSPLANTATION 
Method
20 adult male Wistar rats weighing 300 - 440g each received 
a single intraperitoneal injection of DMNA at a dose of 
50mg/kg to induce acute hepatic failure. 6 hours later 
under ether anaesthesia each rat received an 
intraperitoneal injection of hepatocyte suspension. In each 
case the volume of the suspension was 1ml but the number of 
contained hepatocytes varied. 5 rats received 3.94x10? 
hepatocytes with a viability of 83%; 5 were given 4.12x10? 
hepatocytes with a viability of 84%; 5 received 4.42x10? 
hepatocytes of viability of 78% and the other 5 were given 
6.15x10? hepatocytes with a viability of 84%. The results 
for these rats were compared with a group of 4 rats each 
weighing between 280 and 340g which were given an 
intraperitoneal dose of 50mg/kg DMNA to induce acute 
hepatic failure and then 6 hours later received an 
intraperitoneal injection of HBSS+. In both groups 
monitoring blood samples were taken before induction of 
acute hepatic failure, prior to intraperitoneal injection 
of hepatocytes or HBSS+ and daily till death or sacrifice. 
All rats underwent postmortem examination with removal of 
the liver and any other relevant tissue for histological 
examination.
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Results
2 rats in the hepatocyte group survived the episode of 
acute liver failure with sacrifice at 150 and 216 hours and 
the mean survival for the other 18 was 58 hours with an 
overall mean survival of 71 hours. Both of the surviving 
rats were in the group which received 3.94x10? hepatocytes 
but there was no significant difference in survival amongst 
the dose variations.
Of the rats given intraperitoneal HBSS+ there was a mean 
survival of 56 hours with the rats dying at 44, 53, 57 and 
72 hours. There was no statistically significant difference 
in survival between the two group when analysed by the 
Mann-Whitney test.
Norraotest (mean)
hours 0
hepatocytes 47%
HBSS 34%
hours 72
hepatocytes 5%
HBSS <5%
43!
41!
96
24
12%
5%
144
44%
48
6%
<5%
216
62%
ALT (mean) 
hours 
hepatocytes 
HBSS
hours
hepatocytes
HBSS
0
57
79
72
1320
229
6
509
68
96
24
5104
3360
144
98
48
2055
4449
216
29
AST (mean) 
hours 
hepatocytes 
HBSS
hours
hepatocytes
HBSS
0
215
346
72
7248
1913
6
894
137
96
4275
24
5342
2965
144
319
48
10303
8010
216
92
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AP (mean)
hours 0 6 24 48
hepatocytes 438 349 445 1637
HBSS 361 259 30 566
hours 12 96 144 216
hepatocytes 678 1475 1125 442
HBSS 578
Bilirubin (mean)
hours 0 6 24 48
hepatocytes 6 5 17 52
HBSS 11 18 10 51
hours 72 96 144 216
hepatocytes 61 61 12 5
HBSS 36
Histology
All the livers in the hepatocyte group showed necrosis with 
a mean of 74% necrosis. Both the rats which were sacrificed 
still showed substantial liver damage with 54% and 89% 
hepatic necrosis. 6 of the livers had deposits of 
hepatocytes in the portal vein branches. (Fig. 22) 17 rats 
had deposits within their peritoneal cavities that had not 
been encountered in any of the previously studied groups. 
These were usually positioned subdiaphragmatically but 
could occur anywhere. Microscopy revealed them to contain 
hepatocytes which in about half the cases appeared to be 
viable cells (Fig. 23) although there were a lot of dead 
cells in all the deposits (Fig. 24).
The rats in the HBSS group showed a mean of 67% hepatocyte 
necrosis at death. There were no intraperitoneal deposits 
seen in this group.
When subjected to statistical analysis (Mann-Whitney) there 
were no significant differences between the groups with 
respect to normotest, ALT, AST, alkaline phosphatase or
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Fig. 22. Hepatocytes in portal vein after intraperitoneal 
transplantation. (xlO)
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Fig. 23. Intraperitoneal deposits of live hepatocytes 
(x40)
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Fig. 24. Intraperitoneal deposits of dead hepatocytes 
(x40)
bilirubin levels nor was there any difference between the 
extents of hepatic necrosis.
Conclusion
Despite 2 rats in the peritoneal hepatocellular transplant 
group achieving survival from the hepatotoxin induced liver 
failure there was no significant benefit from the 
hepatocytes administered by either route over the control 
groups in respect of coagulation, biochemical testing, 
survival or degree of histological liver damage. The long 
term survivors in the intrasplenic group without hepatic 
failure served to demonstrate that the procedure of 
intrasplenic injection itself was not detrimental to the 
rat and that the cause of death of the other rats could not 
be attributed to the technique.
Very few hepatocytes were evident in the spleens at death 
so there were certainly not enough functioning hepatocytes 
at this site to sustain the animal. There were however more 
hepatocytes, both ones which looked alive and dead ones, in 
the portal vein branches within the livers and they might 
have been able to contribute to the recovery of the rats.
Of interest were the appearances of deposits of healthy 
looking hepatocytes within the peritoneal cavity as late as 
72 hours after intraperitoneal hepatocyte transplantation. 
Previous reports of this technique have commented that 
hepatocytes had not been recovered from the peritoneal 
cavity (Sutherland 1977, Makowka 1980b).
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In the above experiments hepatocellular transplantation by 
either the intrasplenic or the intraperitoneal site 
appeared to be no better than the non treatment control 
regimes at modifying the course or extent of the hepatic 
failure produced by DMNA in this model in the Wistar rat.
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INTRAPERITONEAL ADMINISTRATION OF CYTOSOL
It has been suggested that in the treatment of acute 
hepatic failure it is not essential to supply intact, 
functioning hepatocytes to improve survival of the 
experimental animal (Makowka 1981) and that some other 
cells such as bone marrow cells produce the same results 
(Makowka 1980c). Cytosol prepared from homogenised liver of 
fetal or partially hepatectomised rats has also proved 
beneficial. Regenerating cytosol has been shown to be 
effective in improving the survival in rats in a 
chemotherapeutic model of acute liver failure (Miyazaki 
1983). Cytosol from homogenised normal adult liver has been 
shown not to improve survival (Makowka 1981). Liver cytosol 
was produced by a different method, from a suspension of 
isolated hepatocytes from normal adult rats and this was 
administered in a previously unreported dosage regime.
Ten male adult Wistar rats weighing 320g - 390g with acute 
hepatic failure were treated with repeated intraperitoneal 
injections of cytosol produced from other similar rats and 
the results compared with rats in acute liver failure 
treated with daily intraperitoneal injections of saline.
Method
Cytosol was prepared from isolated hepatocyte suspension as 
described earlier. Acute hepatic failure was induced by the 
single intraperitoneal injection of 50mg/kg 
dimethylnitrosamine and 6 hours later treatment was
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commenced with intraperitoneal cytosol or control 
injections according to the following regime.
Cytosol group - 2 rats daily injections of cytosol 
equivalent to the contents of 5.7x10^ hepatocytes per day,
2 rats injected daily with cytosol equivalent to the 
contents of 3x10? hepatocytes per day, 4 rats injected 
every second day with cytosol equivalent to the contents of 
3x10? hepatocytes per injection and 2 rats injected every 
third day with cytosol equivalent to the contents of 3x10? 
hepatocytes per injection.
Control group - 4 rats receiving daily injections of 
saline.
The cytosol and the control injections were all given 
intraperitoneally and each injection was of 1ml.
Blood samples were taken for clotting assessment and 
biochemical liver function testing before the induction of 
acute hepatic failure, 6 hours afterwards, before the first 
treatment injection and at daily intervals. At death or 
sacrifice all animals underwent postmortem examination with 
removal of the liver for histological examination.
Results
Mean survival for the cytosol treated group was 95 hours; 
that being 73 and 100 hours for the low dose daily injected 
rats, 100 and 48 hours for the high dose daily injected 
ones, 336{sacrificed), 48, 72 and 48 hours for the high 
dose every second day injections and 72 and 54 hours for 
the high dose every third day treated rats. The mean 
survival for the control rats was 46 hours.
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Normotest (mean)
hours 0 6 24 48 72 96 148 194 240 336
group
cytosol 40% 37% 7% 7% 8% 10% 22% 13% 70% 39%
saline 46% 32% 8% 4%
ALT (mean)
hours 0 6 24 48 72 96 148
group
cytosol 109 85 3626 3711 867 106 152
saline 80 63 1864 1312
AST (mean)
hours 0 6 24 48 72 96 148
group
cytosol 162 201 2768 10648 3470 1104 304
saline 194 104 1912 7282
AP (mean)
hours 0 6 24 48 72 96 ' 148
group
cytosol 321 226 386 523 510 448 708
saline 518 406 420 539
Bilirubin (mean)
hours 0 6 24 48 72 96 148
group
cytosol 9 8 11 65 58 12 12
saline 10 15 27 21
Postmortem
At death 2 of the rats in the cytosol group had 
intraperitoneal haemorrhage and the rats in this group had 
evidence of acute liver failure, except the rat which was 
sacrificed after recovery. The 9 rats with histological 
hepatic destruction had a mean of 71% liver necrosis.
1 of the rats in the saline group had postmortem evidence 
of intraperitoneal haemorrhage. All the control rats had 
liver necrosis with a mean of 67% hepatocyte destruction.
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Fig. 25. Regenerating hepatocytes. (x40)
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The 1 rat which survived in the cytosol group had signs of 
liver regeneration on histology (Fig. 25) and also areas 
showing bridging fibrosis.
Despite the apparent trend towards improved biochemistry at 
24 and 48 hours in the cytosol group, these results failed 
to reach statistical significance (Mann-Whitney). There was 
no significant difference between the groups in respect of 
the extent of hepatocyte necrosis at death. The results do 
show an improvement in survival for the rats treated with 
intraperitoneal cytosol with a significant difference of 
p<0.05.
Conclusion
Other workers have claimed that cytosol prepared from non 
regenerating liver is ineffective at improving the survival 
of rats with acute liver failure (Schwarz 1985). This 
experiment has shown that hepatocyte cytosol prepared from 
isolated cell suspension and given in the regime described 
can produce long-term survivors in a model of liver failure 
with an otherwise 100% fatality. There was also a trend 
toward biochemical improvement in the cytosol treated group 
but it does not reach statistical significance within the 
limited numbers used.
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2 of the rats in this experiment suffered intraperitoneal 
haemorrhage as a result of the repeated injections when 
they had abnormal blood clotting; this risk is not 
desirable in the experimental animal and would be 
unacceptable if the therapy was to be applied clinically. A 
safer means of administering the cytosol requires to be 
found.
Intraperitoneal hepatocyte cytosol from normal adult rats 
when administered in repeated doses improves the survival 
of rats with toxin induced acute hepatic failure.
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REPEATED INTRAVENOUS INJECTIONS OF CYTOSOL .
Twelve rats were treated by repeated intravenous injections 
of rat hepatocyte cytosol beginning 6 hours after the 
induction of acute hepatic failure. The results from these 
rats were compared with a control group of 12 rats which 
received intravenous injections of normal saline at the 
same times.
All the rats were adult male Wistar rats. Those in the 
cytosol group weighed between 275g and 400g and the saline 
controls from 280-370g. Cytosol was prepared as befope.
Acute hepatic failure was induced by a single 
intraperitoneal injection of 50mg/kg dimethylnitrosamine. 
Six hours later the rats received intravenous injections of 
cytosol or saline and these injections were repeated daily 
for up to five doses. Blood samples were taken from each 
rat prior to the induction of acute hepatic failure and 
before each daily injection. Intravenous injections were 
given into, and blood samples taken from a tail vein using 
a 1ml syringe attached to a 25G "Butterfly" needle. From 
the blood obtained the clotting ability was assessed by 
"Normotest" and the biochemical liver function tests of 
alanine transaminase, aspartate transaminase, alkaline 
phosphatase and bilirubin levels were measured. Postmortem 
examinations with removal of the livers for histology were 
performed on all rats at death or sacrifice.
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Results
9 of the rats which received cytosol injections survived 
the experiment with return of clotting and biochemistry to 
pre-liver failure levels. The survivors were sacrificed 
between 365 and 630 hours after the induction of acute 
liver failure. The other 3 animals in this group died at 
48, 72 and 116 hours. All rats in the saline group died of 
acute hepatic failure between 48 and 95 hours.
Norraotest (mean)
hours 0 6 24 48 72 96
cytosol 44% 36% 13% 7% 33% 28%
controls 43% 26% 8% 6% 10%
ALT (mean)
hours 0 6 24 48 72 96
cytosol 79 64 1558 4287 1815 620
controls 76 53 1994 2554 844
AST (mean)
hours 0 6 24 48 72 96
cytosol 215 148 1978 7792 2066 708
controls 192 150 2683 8518 4286 1619
120
40%
120
144
34%
144
146
192
29%
sacr
58%
192
89
sacr
92
120
445
144
214
192 sacr 
164 104
Aik phos (mean) 
hours 
cytosol
hours
cytosol
controls
0 6 24 48 72 96
497 369 534 715 950 1106
363 349 389 548 654 349
(mean)
0 6 24 48 72 96
11 13 11 50 32 15
13 7 11 35 39 15
120
995
144
792
192 sacr 
666 444
120
10
10
144
12
12
192 sacr 
12 9
12 9
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Histology
The 9 surviving rats in the cytosol group showed no 
evidence of hepatocyte necrosis. (Fig. 26) The rat in this 
group dying at 48 hours had 53% hepatocyte necrosis, the 
one dying at 72 hours had 60% and the one dead at 116 hours 
showed 34% hepatocyte necrosis at time of death. In the 
saline group there was a mean hepatocyte necrosis 
measurement at the time of death of 56%.(Figs. 27-29)
Five of the survivors in the cytosol group demonstrated 
bridging fibrosis within the liver and 3 appeared to have 
dilated central veins within the liver lobules.
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Fig. 27. Saline control. (xlO)
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Fig. 28. Survivor after IV cytosol. (x40)
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Fig. 29. Saline control. (x40)
EFFECT OF INTRAVENOUS PLASMA
4 rats were then treated with rat fresh frozen plasma in a 
similar treatment regime to that used above for cytosol and 
the results compared with the cytosol and control groups 
above. Adult male Wistar rats weighing between 270 and 310g 
were injected intaperitoneally with 50mg/kg of 
dimethylnitrosamine to induce acute hepatic failure. Six 
hours later each rat received an intravenous dose of 1ml of 
rat plasma. This had been obtained by bleeding 3 other 
rats, separating the plasma, filter sterilizing and 
freezing it. When required it was thawed, heated to 37°C 
and administered. Blood monitoring was performed as before.
Results
2 rats died at 44 hours after the induction of liver
failure and the other 2 survived. recovered from the
hepatic failure and were sacrificed at 388 hours.
hours 0 6 24 48 72 96 144 192 sacr
Normotest 41% 34% 10% 12% 26% 30% 31% 41%
ALT 93 63 2109 5872 444 85 102 117
AST 182 121 1847 6000 631 117 102 82
AP 500 382 326 830 710 517 447 494
Bilirubin 14 10 27 11 12 12 7 10
Histology
The 2 rats which died had 70% and 75% hepatocyte necrosis 
and the 2 survivors had no hepatocyte necrosis at the time 
of sacrifice. (Figs. 30, 31)
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Fig. 30. Survivor after IV plasma. (xlO)
Fig. 31. Nonsurvivor after IV plasma. (xlO)
ALTERATION IN CYTOSOL DOSAGE
Acute hepatic failure was induced as before in nine adult 
male Wistar rats weighing between 320 and 400g. Six hours 
later the rats were again anaesthetised and each rat was 
given an intravenous injection of cytosol which had been 
prepared from other adult male Wistar rats. Three rats 
received a concentration of cytosol equivalent to the 
contents of 1.02x10? hepatocytes, three were given a 
cytosol with concentration equivalent to 1.9x10? cells and 
three received a concentration of 3.42x10? hepatocytes. The 
doses of intravenous cytosol were repeated daily 
maintaining the same concentration as the initial dose for 
each rat. All cytosol injections had a volume of 1ml.
Blood samples for the measurement of Normotest and 
biochemical liver function tests were taken prior to the 
induction of acute hepatic failure, before each dose of 
cytosol and at regular intervals till sacrifice. Any rat 
recovering from acute hepatic failure was sacrificed when 
well. At death or sacrifice the rats were subjected to a 
postmortem examination with removal of the liver for 
histological review.
Results
One rat in each of the test groups died of acute liver 
failure, at 120 hours in the group given the lowest dose of 
cytosol, at 48 hours in the one receiving the intermediate 
dosage and at 72 hours in the rats given the highest 
concentration. All the surviving rats were sacrificed at 
533 hours.
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Normotest (mean)
hours 0 24 48 72 96 120 168 sacr
low dose 37% 45% 15% 8% 28% 44% 44% 37%
middle dose 40% 31% 14% 7% 23% 40% 37% 42% 50%
high dose 39% 41% 16% 9% 21% 41% 40% 44% 45%
ALT (mean)
hours 0 6 24 48 72 96 120 168 sacr
low dose 88 73 856 941 838 100 97
middle dose 78 57 350 4313 1715 748 202 85 120
high dose 84 63 708 4930 1985 1008 368 126 114
AST (mean)
hours 0 6 24 48 72 96 120 168 sacr
low dose 305 127 891 1270 1015 350 106
middle dose 143 122 980 8240 2126 925 355 200 100
high dose 227 116 830 7826 2212 987 410 410 103
Aik Phos (mean)
hours 0 6 24 48 72 96 120 168 sacr
low dose 453 416 491 916 897 295 453
middle dose 407 352 549 729 960 1232 765 242 389
high dose 423 372 478 698 852 1010 860 235 386
Bilirubin (mean)
hours 0 6 24 48 72 96 120 168 sac
low dose 8 3 10 28 21 20 5
middle dose 16 5 4 39 18 12 15 10 10
high dose 13 8 8 46 40 11 10 15 10
Histology
The surviving rats in each group showed no evidence of 
hepatocyte necrosis. The rat which died at 120 hours in the 
low dose group demonstrated 50% necrosis at time of death, 
the one in the middle dosage group which died at 48 hours 
showed 64% hepatocyte necrosis at time of death and the rat 
which died in the high dose group at 72 hours had 60% 
necrosis. The livers of the surviving rats in the middle 
and high dosage groups showed some bridging fibrosis and 
some of the livers, particularly in the low dose group, had 
dilated central veins.
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ALTERATION IN TIMING OF THE FIRST DOSE OF CYTOSOL
Nine male Wistar rats weighing between 255 and 300g were 
injected intraperitoneally with 50mg/kg of 
dimethylnitrosamine to induce acute hepatic failure. The 
animals were divided into three groups; all to receive 
daily intravenous injections of rat hepatocyte cytosol to a 
maximum of five injections (4 in group 3). The animals in 
group 1 received their first dose at 6 hours after the 
induction of acute liver failure, those in group 2 at 12 
hours after the dimethylnitrosamine and group 3 at 24 
hours. The cytosol used in all groups was from the same 
donor rat and each dose contained the intracellular 
cytoplasmic contents of 1.9x10? hepatocytes. Blood samples 
were taken before each cytosol injection and at intervals 
afterwards till death or sacrifice. Postmortem examinations 
were performed on all rats with removal of the livers for 
histology.
2 rats were given DMNA as above but not given cytosol and 
they were sacrificed, one at 6 hours and the other at 24 
hours, to see the amount of hepatocyte necrosis at these 
times after induction of acute liver failure.
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Results
In group 1 one rat died of liver failure at 72 hours. 
Another rat in this group died of an undiagnosed cause 
while being anaesthetised at 216 hours. By this time in the 
experiment its clotting and biochemical liver function 
tests had returned to the normal range. All rats in group 2 
recovered from the acute hepatic failure and were 
sacrificed. One rat in group 3 died at 72 hours of liver 
failure. All surviving rats in the three groups were 
sacrificed at 365 hours.
Normotest (mean) 
hours 0 6
Group 1 36% 39%
Group 2 29%
Group 3 52%
ALT (mean)
hours 0 6
Group 1 189 103
Group 2 154
Group 3 129
AST (mean)
hours 0 6
Group 1 281 168
Group 2 221
Group 3 136
Aik Phos (mean) 
hours 0 6
Group 1 551 562
Group 2 619
Group 3 643
Bilirubin (mean)
hours 0
Group 1 25
Group 2 10
Group 3 3
6
10
12 24 48 72 96 144 216 365
4% 4% 12% 34% 38% 58% 70%
13% 5% 10% 35% 18% 32% 62% 51%
4% 18% 46% 38% 42% 47% 56%
12 24 48 72 96 144 216 365
4312 3165 364 138 172 142
136 4410 2200 706 330 112 121 141
4554 2467 683 320 162 152 125
12 24 48 72 96 144 216 365
4704 3000 559 228 363 187
312 6090 2607 852 375 139 185 135
6915 3927 840 425 309 201 116
12 24 48 72 96 144 216 365
700 902 1128 765 444 529
600 740 962 1020 1088 629 639 564
797 811 1013 1040 572 538 542
12 24 48 72 96 144 216 365
28 56 10 10 10 10
0 30 32 14 20 8 7 7
32 42 20 11 10 10 10
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Histology
None of the surviving animals showed any evidence of 
hepatocyte necrosis; neither did the rat in group 1 which 
died at 216 hours.
The rat in group 1 which died at 72 hours showed 70% 
hepatocyte necrosis at the time of death and the one*which 
died at 72 hours in group 3 had 47% hepatocyte necrosis. 
The livers of the surviving rats again showed bridging 
fibrosis. In the untreated rats there was no evidence of 
hepatocyte necrosis at 6 hours (Fig. 32) but at 24 hours 
there was 60% necrosis (Fig. 33).
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Fig. 33. 24 hours after DMNA. (xlO)
CYTOSOL ADMINISTRATION AFTER 24 HOURS
To determine if hepatocyte cytosol administered in this 
regime was effective treatment if the first dose was given 
later than 24 hours after the induction of hepatic failure 
a further 10 rats were studied. These adult male Wistar 
rats weighing between 270 and 370g each received an 
intraperitoneal injection of 50mg/kg of dimethylnitrosamine 
to induce acute hepatic failure. 5 of the rats (group 1) 
were given their first dose of cytosol at 24 hours after 
the dimethylnitrosamine and the other 5 (group 2) received 
the first dose at 30'hours after the induction of hepatic 
failure. Each 1ml cytosol injection contained the 
cytoplasmic content of 3x10? hepatocytes. The rats were 
monitored as previously. All surviving animals were 
sacrificed and postmortems with histological examination of 
the livers were undertaken.
In conjunction with this experiment 2 control animals were 
also studied. Both of these rats, weighing 280 and 360g, 
underwent induction of acute hepatic failure as above by a 
single intraperitoneal injection of dimethylnitrosamine.
One rat received an intravenous injection of saline at 24 
hours after the induction of acute hepatic failure and the 
other a similar saline injection at 30 hours.
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Results
In group 1 (24 hours) 4 of the 5 animals died of acute 
liver failure at 48, 55, 60 and 140 hours and 1 survived to 
be sacrificed at 360 hours. All of group 2 (30 hours) died 
of liver failure at 31, 40, 40, 48 and 81 hours. The 24 
hour saline control died of liver failure at 40 hours and 
the 30 hour control died at 30 hours.
Normotest (mean)
hours 0 24 30 48 72 96 168 216 312 360
Group 1 49% 13% 5% 27% 18% 35% 39% 43% 70%
Group 2 46% 4% 4%
Control 24 51% 19%
Control 30 39% <5%
ALT (mean)
hours 0 24 30 48 60 72 168 216 312 360
Group 1 80 1330 190 4398 70 90 135 105
Group 2 88 5985 6379 22 *
Cont. 24 85 1115 >7500
Cont. 30 65 4920
AST (mean)
hours 0 24 30 48 60 72 168 216 312 360
Group 1 281 1540 7595 12185 85 155 95 85
Group 2 256 6525 11530 2016
Cont.24 225 1355 >7500
Cont.30 385 10290
Aik Phos (mean)
hours 0 24 30 48 60 72 168 216 312 360
Group 1 319 310 498 751 410 360 390 452
Group 2 402 380 667 601
Cont.24 380 385 624
Cont.30 225 370
Bilirubin (mean)
hours 0 24 30 48 60 72 168 216 312 360
Group 1 14 10 49 59 10 15 5 10
Group 2 10 25 38 58
Control 24 10 
Control 30 15
21 27
53
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Histology
In Group 1 the three rats which died between 48 and 60 
hours after the induction of acute hepatic failure showed 
hepatocyte necrosis of 64% of the liver. The rat dying at 
140 hours had 14% hepatocyte necrosis and the rat which was 
sacrificed had no evidence of hepatocyte destruction. In 
Group 2 the mean amount of hepatocyte destruction was 72%. 
The 4 rats dying between 31 and 48 hours had hepatocyte 
loss of 74% and the one dying at 81 hours had 60% 
hepatocyte necrosis. The control animal receiving saline at 
24 hours had 73% hepatocyte necrosis and the one receiving 
saline at 30 hours had 56% hepatocyte loss.
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EFFECT OF RAT LIVER CYTOSOL ASSESSED AT THE TIME OF DEATH 
OF CONTROL RATS.
Acute hepatic failure was induced as before in a further 
eight male Wistar rats, weighing between 330g and 410g. The 
rats were divided into two groups and paired. One of each 
pair received an intravenous injection of rat hepatocyte 
cytosol at 6 hours after the induction of acute liver 
failure and at daily intervals and the other one was given 
intravenous saline at the same times. Upon the death"of one 
of the pair the other one was sacrificed. Blood samples 
were taken before each treatment or control injection to 
monitor Normotest, and biochemical liver function tests. At 
death or sacrifice the rats underwent a postmortem with 
removal of the liver for histology and assessment of liver 
necrosis and for analysis of possible liver regeneration. 
Liver regeneration was assessed by counting the number of 
hepatocyte nuclei showing mitotic figures and expressing 
this as a percentage of the total number of nuclei within 
the same area.
Results
All of the control rats and one of the cytosol rats died at 
72 hours and the remaining cytosol treated rats were 
sacrificed at this time. (One of the control rats had died 
a few hours earlier, considered to be at about 68 hours but 
its pair was sacrificed at 72 hours.)
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Normotest (mean)
hours
cytosol
saline
0
38'
38'
39'
32'
24
30%
9%
48
<5%
<5%
72
5'
<5'
ALT (mean)
hours 0
cytosol 57
saline 62
6
55
50
24
1762
1096
48
4600
72
1631
1127
AST (mean)
hours 0
cytosol 192
saline 148
6
131
122
24
2085
2737
48
4850
72
3082
4097
Aik Phos (mean) 
hours 0
cytosol 321
saline 292
6
298
239
24
362
345
48
545
72
652
583
Bilirubin (mean) 
hours 0
cytosol 11
saline 12
6
10
10
24
20
10
48
20
72
36
57
Histology
In the cytosol treated rats the mean amount of hepatocyte 
necrosis was 51% (Fig. 34) and in the saline group it was 
60% (Fig. 35). Signs of hepatic regeneration were seen in 
both groups but the rats in the cytosol group showed more 
regeneration than the controls. In the cytosol group the 
mean mitotic index measurement was 9.6% and in the cytosol 
treated group it was 13.3%. When analysed statistically 
(Mann-Whitney) this was a significant difference (p<0.005) 
The areas of regenerating cells in both groups can be seen 
in Figs. 36 and 37.
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Fig. 37. IV saline, 72 hour death. (x40)
CONCLUSIONS
When subjected to statistical analysis there was a 
significant difference between the survival rates of the 
cytosol treated rats and the saline controls in the first 
experiment p<0.005. However, the biochemical and 
coagulation results showed no difference between the 
groups. The difference in the amount of hepatocyte necrosis 
observed was also very significant p<0.001. This reflects 
the longer survival since the sacrificed animals had no 
necrosis at postmortem.
When the plasma group was considered there was no 
statistically significant difference in survival between 
either the plasma and the earlier saline control group or 
between the plasma and the intravenous cytosol group. 
Neither were there any differences between the plasma group 
and either of the preceding groups in respect of 
biochemistry, coagulation or hepatocyte necrosis. This 
result raises the question as to whether the cytosol is 
acting purely as colloid and maintaining the intravascular 
volume or whether it has a stimulatory effect to 
regeneration on the hepatocytes.
The variations in cytosol dosage showed no differences 
amongst the groups in any of the results monitored, 
indicating that all of these doses were equally effective.
In the experiment giving the first dose of cytosol at 
different times it was seen that there were no differences
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amongst the groups in relation to survival, biochemical 
measurement of liver function, coagulation results or the 
degree of liver necrosis. It was therefore evident that the 
cytosol was as effective when the first dose was given at 
12 and 24 hours as it was when treatment was commenced at 6 
hours after the induction of hepatic failure. When the 
timing of the first dose was extended after 24 hours there 
appeared to be a difference in survival between the rats 
treated from 24 hours compared with the rats where 
treatment was delayed till 30 hours. The difference did not 
reach statistical significance when assessed by the Mann- 
Whitney test (p<0.07). There was a statistically 
significant difference between these groups in the amount 
of hepatocyte necrosis seen (p<0.05). It therefore appears 
that cytosol is less effective if administered more than 24 
hours after the induction of the liver failure.
When the animals were studied in the paired experiment 
there were no differences in the biochemistry or 
coagulation results between the groups. Neither was there 
any significant difference in the extent of hepatocyte 
necrosis recorded between the animals receiving cytosol and 
those given saline. There was, however, significantly more 
hepatocyte regeneration in the rats treated with cytosol. 
This suggests that cytosol is doing more than just 
maintaining volume and that it could be stimulating 
hepatocytes to regenerate at a faster rate than in the 
control animals.
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SUMMARY
Rat hepatocyte cytosol administered intravenously in 
repeated doses improves the survival of rats with toxin 
induced hepatic failure and appears to do so by increasing 
the rate of regeneration of the surviving hepatocytes. It 
is effective when the first dose is given up to 24 hours 
after the induction of liver failure by which time 
hepatocyte necrosis is already established.
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IN-VIVO PARTIAL CHARACTERISATION OF HEPATOCYTE CYTOSOL
The hepatocyte cytosol used in the previous experiments is 
a mixture of chemicals, cellular organelles and other 
components of the cytoplasm of the hepatocyte. It is 
therefore necessary to try to define which component or 
combination of factors is responsible for the improved 
survival of the rats treated with cytosol in the 
hepatotoxin-induced acute hepatic failure model.
In an attempt to separate different components cytosol waP 
heated at two different temperatures. Another batch of 
cytosol was dialysed across a membrane allowing the passage 
of molecules smaller than 8,000 molecular weight.
Methods
Preparation of heat-stable fraction.
Cytosol was prepared as before but prior to sterilisation 
one batch, with an hepatocyte concentration of 3.0x10? per 
ml of cytosol, was heated at 56^0 for 30 minutes. A second 
specimen of cytosol, with an hepatocyte concentration of 
3.1x10? per ml was heated at 65°C for 15 minutes and a 
third cytosol (4.5x10? hepatocytes per ml) was also heated 
at 65^0 for 15 minutes.
Preparation of dialvsed cvtosol.
Cytosol was prepared as previously but before filter 
sterilising it was put inside a dialysis membrane tube with 
a pore size of molecular weight cutoff of 6,000 - 8,000 
("Spectra/Por 1" membrane; Spectrum Medical Industries). It
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was dialysed for 24 hours against Hank's balanced salt 
solution with calcium and magnesium, changing the dialysate 
twice during the process.
15 male adult Wistar rats weighing between 310 and 360g 
were given acute hepatic failure by an intraperitoneal 
injection of 50mg/kg of dimethylnitrosamine. 6 hours after 
this each rat received its first intravenous injection of 
modified cytosol, according to the following regime.
Group 1 - 3  rats - cytosol of 3.0x10? hepatocytes heated at
56^C for 30 minutes.
Group 2 - 4  rats - cytosol of 3.1x10? hepatocytes heated at
65°C for 15 minutes.
Group 3 - 2  rats - cytosol of 4.5x10? hepatocytes heated at
65°C for 15 minutes.
Group 4 - 6  rats - dialysed cytosol.
Each rat then was given the same modified cytosol as its 
first injection at daily intervals to a maximum of 5 doses. 
Blood samples were taken from the rats' tail veins for 
Normotest and biochemical liver function testing prior to 
the induction of acute liver failure, before each dose of 
modified cytosol and at death. Postmortem examinations were 
performed on all animals and the livers removed for 
histological examination.
Results
All rats died of liver failure. Those in group 1 died at 
96, 102 and 144 hours; in group 2 at 56 60 65 and 96 hours; 
in group 3 at 75 and 120 hours and in group 4, 2 die at 60 
hours, 1 at 65, 1 at 70 and 2 at 90 hours.
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Normotest (mean)
hours 0 6 24 48 60 72 96
Group 1 48% 26% 4% 4% 10%
Group 2 36% 41% 6% 4% 4%
Group 3 27% 40% 9% 4% 5%
Group 4 31% 33% 8% 4% 4%
ALT (mean)
hours 0 6 24 60 72 96
Group 1 95 68 3414 1770 116
Group 2 75 62 2211 1271 250
Group 3 68 76 2356 615
Group 4 76 95 607 2415 82 24
AST (mean)
hours 0 6 24 60 72 96
Group 1 229 163 4325 1835 1690
Group 2 137 126 2563 5853 967
Group 3 80 335 2628 3970
Group 4 162 182 844 8482 4415 1912
A P (mean)
hours 0 6 24 60 72 96
Group 1 495 272 485 785 456
Group 2 295 153 352 483 636
Group 3 303 217 232 395
Group 4 286 298 246 522 526 520
Bilirubin (mean)
hours 0 6 24 60 72 96
Group 1 15 20 21 10 20
Group 2 12 22 33 45 14
Group 3 10 29 56 43
Group 4 22 18 15 35 71 40
102
13%
102
415
120
34
102 120
1280
989
102
1015
120
722
102
18
120
33
Histology
At death the rats in group 1 showed 60% hepatocyte 
necrosis, those in group 2, 56%, the ones in group 3 had 
48% hepatocyte loss and the ones that were given dialysed 
cytosol (group 4) had 55% hepatocyte necrosis.
When these results were compared .with those for the crude 
cytosol and control saline injections in chapter 9 and 
analysed statistically (Mann-Whitney) the coagulation, 
biochemical, survival and extent of hepatocyte necrosis
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results were similar to those for the control saline 
injections. The heated and the dialysed cytosol tested here 
gave poorer results for survival and hepatocyte necrosis 
than the whole crude cytosol p<0.05.
Conclusion
The component of hepatocyte cytosol producing the improved 
survival of rats with acute hepatic failure would appear to 
be able to pass through a dialysis membrane of pore size 
6,000 - 8,000 molecular weight. This suggests that it is a 
molecule possibly below 6,000 daltons but definitely, 
smaller than 8,000 daltons. The active component is also 
destroyed by heating at 56^0 for 30 minutes and 65°C for 15 
minutes and therefore must be considered to be heat labile.
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EFFECT OF RAT HEPATOCYTE CYTOSOL ON DNA SYNTHESIS IN RAT
HEPATOCYTE CULTURE.
In the experiments described earlier it was seen that rat 
hepatocyte cytosol improved the survival of rats with 
hepatotoxin induced acute liver failure when administered 
intravenously in repeated doses. However, it was not 
possible to discern the mechanism for this. One possibility 
is that a component of the cytosol may have a stimulatory 
effect on DNA synthesis and so increase the regeneration 
rate of the surviving periportal hepatocytes to the extent 
that enough liver tissue is again functioning before the 
rat reaches a terminal stage of hepatic failure.
The effect of rat liver cytosol on DNA synthesis in rat 
hepatocyte culture was assessed to determine whether 
stimulatory effects could be demonstrated.
Materials and methods.
In three separate experiments hepatocyte suspensions were 
produced as previously described by collagenase perfusion 
of the liver of a Wistar rat. 3 x 10^ hepatocytes were 
placed on each collagen coated cell culture plate. The 
cells were cultured in William's E medium (Williams 1974) 
without Arginine but with Ornithine (0.07mg/ml) and 
containing glutamine (2mg/ml), penicillin (lOOU/ml), 
streptomycin (lOOjug/ml), hydrocortisone (2/ig/ml) and 
insulin (0.015U/ml). The medium was changed daily. At the 
beginning and at each medium change cytosol, EGF and TGFjS
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were added according to the following scheme. Three plates 
were used in each group.
Experiment 1
a) control plates i) no addition
ii) EGF (0.85nmol)
iii) TGFjS (lOpmol)
b) test plates i) 20pl cytosol
ii) 60pl cytosol
iii) 5pl cytosol
iv) 60pl cytosol + TGFjS (lOpmol)
v) 60pl cytosol + EGF (0.85nmol)
The cytosol used in this experiment was from rat 72 with 
1ml of cytosol prepared from 3.06x10? hepatocytes. The 
cells were cultured for 72 hours.
Experiment 2
a) control plates i
ii
iii
b) test plates i
ii
iii
iv
V
vi
vii
viii
ix
X
no addition 
EGF (0.85nmol)
TGFjS (lOpmol)
5pl cytosol + EGF (0.85nmol) 
lOpl cytosol + EGF "
30/il cytosol + EGF "
60pl cytosol + EGF "
5pl cytosol + TGFjS (lOpmol) 
60pl cytosol + TGFjS "
5pl cytosol 
lOpl cytosol 
30pl cytosol 
60pl cytosol
The cytosol used here was obtained from rat 114 with 1.3ml 
of cytosol containing extract from 3.09x10? hepatocytes 
(2.38xl0?cells/ml). Cells were cultured for 72 hours.
Experiment 3
a) control plates
b) test plates
i) no addition (a)
ii) no addition (b)
iii ) EGF (0.85nmol) (b)
i) 5pl cytosol (a)
ii) lOpl cytosol (a)
iii) 60pl cytosol (a)
iv) 5pl cytosol (b)
V) lOpl cytosol (b)
vi) 60pl cytosol (b)
vii) 5pl cytosol f EGF
viii) lOpl cytosol + EGF
ix) 60pl cytosol + EGF
X) 5pl cytosol 4- EGF
xi) lOpl cytosol + EGF
xii) 60pl cytosol + EGF
(0.85nmol) (a)
(a)
(a)
(b) 
(b) 
(b)
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The. cytosol used in this experiment was from rat 94 with
0.8ml of cytosol containing the cytoplasmic contents-of 
1.9x10? hepatocytes (2.4xl0?cells/ml). In the plates marked
(a) the cells were cultured for 48 hours and those marked
(b) for 72 hours.
Cells were maintained in culture for 48 or 72 hours with 
daily medium changes and thymidine (Ipcur/ml) added for 
the final 24 hours.
To halt growth and extract the DNA a modification of the 
method used by McGowan (1981) based upon that of Munro and 
Fleck (1966) was used. The cells on the plate were washed 
with PBS and cold (4^C) 5% trichloroacetic acid (TCA) was 
added and the plates cooled to 4®C. Two 1.5ml washes with 
5% TCA were then performed followed by two 1.5ml washes 
with 95% ethanol. Solubilization was established by adding 
1ml of 0.3N KOH for 1 hour at 37®C. After this the plates 
were scraped and the cells transferred to a tube containing 
Img/ml bovine serum albumen (BSA) . To this was added 400/il 
20% TCA at 4°C and left for at least 10 minutes. It was 
then centrifuged at lOOOrpm for 1 minute at 4°C and the 
supernatant removed and the cells washed with 1ml 5% TCA 
and centrifuged again. The resultant pellet was hydrolyzed 
in 200/il 5% TCA for 15 minutes at 90°C and then centrifuged 
at 3000rpm for 15 minutes. From the supernatant lOOpl was 
used in the diphenylamine assay to measure the DNA 
concentration and 40/il was put in 4ml of Optiphase X and 
the disintegrations per minute were measured in a 
scintillation counter.
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DNA concentration was measured by the diphenylamine assay 
(Burton 1956) using lOOjul of the liver extract in 5% TCA 
added to 400pl 0.5N perchloric acid (PCA) and 0.5ml of 
reagent. The tubes were stoppered and left to stand at room 
temperature overnight in the dark. Samples were placed in 
2ml cuvettes and read in the spectrophotometer at OD 595. 
The results were read from a standard curve prepared from 
readings at Ipg/lOOml TCA, 2pg/100ml, 3pg/100ml, 4pg/100ml, 
5pg/100ml, 6pg/100ml and a blank of 100/il TCA.
Results 
Experiment 1
'H disintegrations / pg DNA
Plates 1 2 3 mean
C i) 31548 28777 32496 30940
ii) +EGF 155668 168709 161421 161932
iii) +TGFjS 11861 7800 13109 10923
T i) +20c 20057 16526 19627 18736
ii) +60c 19236 22087 19189 20170
iii) +5c 34608 27989 26117 29571
iv) +60c+TGFj3 15270 26607 4621 15499
V) +60c+EGF 197082 174985 172978 181681
Experiment 2
disintegrations / jug DNA
Plates 1 2 3 mean
C i) 7512 8697 12256 9488
ii) +EGF 100103 99833 99968
iii) +TGFj3 6397 6612 9086 ‘ 7365
T i) +5C+EGF 60380 56494 56950 57941
ii) +10C+EGF 44933 60714 52823
iii) +30C+EGF 25879 28598 27961 27479
iv) +60C+ÉGF 34639 30764 35797 33733
V) +5c+TGFjS 2406 2350 2234 2330
vi) +60c+TGFjS 3428 3889 3056 3457
vii) +5c 2679 2836 3918 3144
viii) +10c 24419 24262 22592 23757
ix) +30c 25135 36332 38023 33163
X) +60c 54368 52640 54260 53756
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Experiment 3
*H disintegrations / pg DNA
Plates 1 2 3 mean
C i) (a) 28444 23437 26871 26251
ii ) (b) 16666 23287 34341 24765
iii) +EGF (b) 180828 190299 193921 188349
T i) +5c (a) 30227 31747 25242 29072
ii ) +10c (a) 24280 22234 26969 24495
iii) +60c (a) 7372 24948 12704 15008
iv) +5c (b) 23162 23880 24390 23811
V) + 10c (b) 24096 22592 19508 22065
vi) +60c (b) 20690 17767 12831 17096
vii) +5C+EGF (a) 180588 77007 175097 144231
viii) +10C+EGF (a) 162051 212774 166602 180476
ix) +6 Oc+EGF (a) 111448 77831 104928 98069
x) +5C+EGF (b) 140959 148162 115031 134717
xi) +10C+EGF (b) 128970 170369 140700 146680
xii) +6 Oc+EGF (b) 125762 141673 111019 126151
In experiment 1 the cytosol reduces the amount of DNA
synthesized in a dose related pattern when compared with 
the control plates. The high concentration of cytosol 
however appears to lessen the inhibitory effect of TGFjS and 
not to interfere with the stimulatory effect of EGF.
In experiment 2 at the lowest dose of cytosol used it 
appears to have an inhibitory effect on DNA synthesis but 
as the concentration of cytosol increases there is a dose 
dependant stimulatory effect. When given with TGFjS the 
combination is more inhibitory than TGFjS alone. The cytosol 
is seen to have a dose dependant inhibitory effect when 
given with EGF but its negative effect on DNA synthesis is 
not sufficient to counteract the stimulation of cell growth 
produced by the EGF.
Again in experiment 3 the cytosol is seen to have an 
overall inhibitory effect on DNA synthesis. The phenomenon 
is still dose dependent and the rate of decline in cell
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regeneration is more pronounced in the shorter experiments 
when the DNA was measured earlier after the administration 
of the cytosol. Cytosol was shown to reduce the effect of 
EGF but in the longer experiment the dose did not appear to 
be of such significance.
There is an inconsistency amongst the results of these 
experiments and the stimulatory effect seen in experiment 2 
may be due to error. The measurements of DNA by the 
diphenylamine assay for the 10/il, 30pl and 60/il cytosol 
plates were abnormally low in this experiment. No 
explanation for this was evident but the experiment must be 
repeated before the result is accepted.
Since the plates incubated with cytosol in the other 
experiments showed inhibition of cell regeneration, and 
cytosol did not reverse the effect of TGF/5 or enhance the 
effect of EGF, cytosol must be considered inhibitory to DNA 
synthesis.
On inspection of the cultured hepatocytes in each 
experiment there was an obvious difference in the cells 
between the plates which had been given cytosol and those 
which had not. The cells cultured with cytosol were seen to 
have rounded up compared to the control ones which retained 
a flattened appearance. (Figs. 38-42)
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Fig. 38. Rat hepatocytes, collagen control
Fig. 39. Rat hepatocytes, control EGF.
Fig. 40. Rat hepatocytes, 5/il cytosol + EGF.
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Fig. 41. Rat hepatocytes, lOpl cytosol + EGF.
Fig. 42. Rat hepatocytes, 60/il cytosol + EGF
Discussion.
In 1981 Makowka showed that normal adult rat hepatocyte 
cytosol had an inhibitory effect on DNA synthesis whereas 
cytosol prepared from regenerating rat liver was 
stimulatory in the hepatocyte culture situation. This he 
attributed to the switching on of "growth factors" by the 
stimulation to regeneration but assumed that in the normal 
resting situation the "factors" produced by the liver were 
inhibitory to cell division. The results from the above 
experiments could be explained in this way. It is of 
interest to note the more pronounced inhibition at an 
earlier time in experiment 3 since in an in vivo experiment 
in rats which had undergone partial hepatectomy normal 
adult rat cytosol was shown to have an initial inhibitory 
and then a stimulatory effect on liver DNA synthesis 
(Makowka 1983). Michalopoulos (1982) suggested that normal 
liver cytosol contained inhibitory and stimulatory factors 
and that the inhibitory ones predominated at higher 
concentrations. These experiments warrant repeating with 
incorporation at different times to see if the normal adult 
rat cytosol produced in this study does have a genuine 
effect upon cell regeneration or if its benefit to the 
survival of the rats in the hepatic failure model is 
dependant on some other mechanism of action.
The cell culture plate is a very controlled environment 
compared with the intact animal and it may be that cytosol 
though increasing regeneration in the in vivo experiments
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requires other cofactors to be present for it to exert its 
effect and so it is ineffective when used alone.
The inhibition of DNA synthesis seen in these experiments 
suggests that the effect of cytosol encountered in the 
acute hepatic failure rat in not due to a direct stimulus 
to the hepatocyte causing an increase in the rate of 
hepatocyte regeneration.
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IN-VIVO ASSESSMENT OF HUMAN HEPATOCYTE CYTOSOL IN ACUTE
HEPATIC FAILURE IN RATS
To investigate if the substance responsible for improving 
the survival of rats with toxin-induced acute liver failure 
is specific for rat hepatocyte cytosol, cytosol produced 
from human hepatocytes was administered to rats using the 
same model of hepatic failure.
Materials and methods
Human hepatocyte cytosol was prepared by a modification of 
the method used in rats. A piece of human liver, weighing 
138g, obtained from a multiorgan donor was placed on the 
perfusion platform and two hepatic vein branches were 
cannulated with 14G cannulae. The perfusion was begun with 
1000ml Hank's balanced salt solution (HESS) without calcium 
or magnesium, followed by 500ml HESS with O.SmM EGTA and 
then 400ml HESS. After this the liver was perfused with an 
enzyme solution of 300ml HESS containing 4ml SOOmM calcium 
chloride, ISOmg collagenase H, 300mg dispase, ISOmg 
hyaluronidase and 15mg deoxyribonuclease which was 
recirculated at 65ml/min for 27 minutes. The liver was then 
cut and the hepatocytes in the centre shed and washed in 
HESS with calcium and magnesium. The cells were then 
filtered through gauze and nylon mesh and the suspension 
centrifuged at 300rpm for 3 minutes. The supernatant was 
removed and the cells resuspended in HESS with calcium and 
magnesium and centrifuged twice. Following final 
resuspension the volume of the cell suspension was made to 
25ml. This cell suspension had a viability of 89% as 
measured by trypan blue exclusion and a cell concentration
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of 2.12x10*^ cells per ml. This was a total hepatocyte yield 
of 5.3x10® cells in 25ml. This suspension was subjected to 
ultrasound bombardment in the soniprep to break down the 
cellular structure, at a power setting of 14 for 3 minutes. 
It was then ultracentrifuged at 40,000rpm for 90 minutes. 
The supernatant was removed, filter sterilised and 
dispensed into ampoules each of which contained a quantity 
of cytosol equivalent to the cytoplasmic contents of 
2.65x10^ hepatocytes. This was stored at -20^C until 
required.
Four adult male Wistar rats weighing between 300 and 325g 
were injected intraperitoneally with 50mg/kg of 
dimethylnitrosamine. Six hours later each rat was given an 
intravenous injection of 1ml human hepatocyte cytosol. The 
cytosol injections were repeated daily up to five doses. 
Blood samples were taken from the tail veins of the rats 
before the induction of acute hepatic failure, before each 
cytosol injection and at intervals afterwards. All animals 
surviving the hepatic failure were sacrificed and 
postmortems were performed on all rats at death or 
sacrifice with removal of the liver for histological 
examination.
Results
Two of the rats died of acute liver failure, at 75 and 116 
hours after the induction of hepatic failure and the other 
two survived the experiment and were sacrificed when well 
at 388 hours.
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Fig. 43. Survivor after human cytosol. (xlO)
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Fig. 44. Nonsurvivor after human cytosol. (xlO)
Discussion
From this experiment it is seen that human hepatocyte 
cytosol contains a substance which is capable of 
successfully treating rats with toxin induced acute hepatic 
failure. This may be the same as the constituent of rat 
hepatocyte cytosol which produces the same result. The rats 
received repeated doses of the xenogeneic substance without 
exhibiting any overt signs of immunological reaction. There 
is obviously an antigenic potential from the foreign 
protein contained in the cytosol but it should be free of 
cell membrane antigens. These findings, however, can not be 
reversed to suggest that rat cytosol could safely be 
administered to humans.
A method has been described to prepare cytosol from human 
hepatocytes. When this is administered to rats with 
hepatotoxin induced acute hepatic failure it produces long 
term survival and recovery from the liver failure. The 
cytosol is easily prepared and can be stored frozen till 
needed. If it were to produce the same results in humans 
with fulminant liver failure this could be a beneficial 
addition to the treatment regime for some of these 
patients.
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EFFECT OF HUMAN HEPATOCYTE CYTOSOL ON DNA SYNTHESIS IN 
HUMAN HEPATOCYTE CULTURE.
To investigate if any substance contained within the 
cytosol of human hepatocytes was capable of increasing the 
rate of DNA synthesis in human liver tissue the crude human 
hepatocyte cytosol was added to human hepatocytes in tissue 
culture.
Materials and methods.
Hepatocytes were obtained as in the previous chapter from 
pieces of human liver. The hepatocytes to be cultured were 
from the liver of a 50 year old adult male organ donor and 
the cells for hepatocyte cytosol production were from the 
liver of a ten year old brain dead boy. For cytosol 
production the cell suspension was suspended to a volume of 
30ml in HESS with calcium and magnesium and subjected to 
the soniprep at power 14 for 5 minutes and then 
ultracentrifuged at 40,000rpm for 90 minutes. The 
supernatant was removed and filter sterilised. Each 1ml of 
this cytosol contained the cytoplasmic contents of 
3.518x10? hepatocytes. For the cell culture there was a 
total yield of 4.7x10? hepatocytes with a cell viability as 
assessed by trypan blue exclusion of 82%.
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1.5ml of hepatocyte suspension containing 600,000 cells was 
placed on to each collagen coated cell culture plate and 
the hepatocytes were cultured as described earlier for rat 
hepatocytes. The medium was changed every 24 hours and at 0 
hours, 24 hours and 48 hours cytosol was added to the test 
plates according to the following scheme, 
control plates
test plates
i) no addition
ii) EGF (0.85nmol)
iii) TGFjS ( lOpmol)
i) lOjul cytosol
ii) lOjul cytosol + EGF
iii) lOjul cytosol + TGFjS
iv) 60/il cytosol
v) 60jul cytosol + EGF
vi) 60/il cytosol + TGFjS
Three plates were included in each of the nine groups.
At 48 hours thymidine (l^currie/ml) was added to each 
plate and the growth stopped at 72 hours. DNA analysis was 
performed as described in the chapter about rat hepatocyte 
culture.
Results.
'H disintegrations / jug DNA
Plates 1 2 3 (mean)
C i) 2125 3889 1822 2612
ii) +EGF 4071 4347 4905 4441
iii) +TGFjS 1340 1475 1952 1589
T i) +10c 770 879 561 736
ii ) +10C+EGF 3474 2063 864 2134
iii) + 10C+TGF/S 105 159 100 121
iv) +60c 500 386 378 421
V) +60C+EGF 808 302 153 421
vi ) + 60C+TGF/3 107 106 50 88
As can be seen from the above table human hepatocyte 
cytosol at both the doses used has an inhibitory effect on
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DNA synthesis and this effect appears to be dose related 
with the higher dose producing the greater inhibition. At 
low dose the cytosol negates the stimulatory effect of EGF 
and at higher dose cancels all EGF effect completely. The 
cytosol effect is additive to the inhibitory effect of 
TGFjS.
The cells in the tissue culture looked different when they 
had been incubated with cytosol. By 48 hours the low dose 
cytosol plates (Figs. 45, 46) showed less cell adherence to 
the plate and the higher dosage cell demonstrated a rounded 
abnormal appearance (Fig. 47). At 72 hours the lower dose 
hepatocytes were very unhealthy (Fig. 48) and most of the 
cells in the higher dosage plates were dead (Fig. 49) .
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Fig. 45. Human hepatocytes, control
%Fig. 46. Human hepatocytes, 30/il cytosol at 48 hours.
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Fig. 47. Human hepatocytes, 60pl cytosol at 48 hours.
Fig. 48. Human hepatocytes, 30/il cytosol at 72 hours.
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Fig. 49. Human hepatocytes, 60/il cytosol at 72 hours.
Discussion.
The results agree with the findings of Makowka(1981) using 
cytosol prepared from the liver of a normal adult rat in 
rat hepatocyte cell culture, when it was postulated that 
non regenerating liver produces an inhibitory factor to 
cell growth and division. The concentrations of cytosol 
used in this experiment are greater than the doses of 
cytosol given to the intact rats. Here the contents of 
3.5x10® and 2.0x10® hepatocytes were given directly to 
6x10® cells compared with the contents of 3.0x10? 
hepatocytes being given to an approximate liver cell 
population of 1.0x10^ cell after distribution throughout 
the body of the intact rat. Since the inhibitory effect 
appears to be dose dependant lower doses of cytosol may 
produce a different result in cell culture studies.
Cytosol does not appear to produce its effect on 
hepatocytes by encouraging regeneration when directly 
applied in controlled conditions but it could still promote 
cell growth and division by acting upon another substance 
or mechanism in the intact animal. The cytosol effect in 
the animal could be dependant upon regenerative factors 
circulating in the rat because of the liver failure or even 
by negating the effect of the growth inhibitory factors.
In 1983 Makowka demonstrated that although normal rat liver 
cytosol in rat hepatocyte culture produced an initial 
inhibition of DNA synthesis there was a significant 
increase in DNA synthesis at 31-40 hours. In the experiment
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above the was given at 48 hours and the uptake measured 
at 72 hours so it is possible that the timing of the 
measurements needs adjustment, and that any positive effect 
of the cytosol was missed.
Human liver cytosol as assessed in this experiment has an 
inhibitory effect on DNA synthesis and cell regeneration in 
human hepatocyte culture.
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DISCUSSION
Fulminant hepatic failure produces a considerable mortality 
(85%) despite numerous clinical treatments which have been 
employed over the last 20 years (Christensen 1984). To date 
only orthotopic liver transplantation offers a remedy which 
produces better survival figures than conventional medical 
therapy (Vickers 1988). Damaged liver is capable of 
regeneration and there is evidence of liver cell 
proliferation even in episodes of acute liver failure which 
prove fatal (Milandri 1980). It is therefore postulated 
that patients' lives could be saved if a) patients could be 
kept alive long enough for adequate liver function to 
recover, b) new liver is implanted or c) attempts are made 
to increase the rate of liver regeneration.
The clinical study undertaken in an acute liver failure 
referral unit showed that the largest single group of 
patients were those who had taken a deliberate overdose of 
paracetamol. This drug is converted in the liver to an 
arylating agent which is normally detoxified by conjugation 
with glutathione. However, if the dose of paracetamol is 
large enough to deplete the liver stores of glutathione 
there is extensive arylation of the intrahepatic 
macromolecules and the hepatocytes die. (Mitchell 1974) 
Cysteine or more commonly acetylcysteine, if given to 
patients who have taken enough paracetamol to be at risk of 
developing liver failure and at a time when it can 
counteract the paracetamol, is effective therapy in 
prevention of liver failure. The high incidence of grade IV
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hepatic coma seen in the present study does not reflect the 
picture of paracetamol overdose seen in general medicine 
since patients had to have evidence of deranged hepatic 
function before admission to the unit. These patients 
usually presented late after the ingestion of the drug and 
were not eligible for acetylcysteine therapy.
The second large group was that of patients with viral 
hepatitis, most of these were considered to have non A non 
B hepatitis as a diagnosis of exclusion in patients who 
appeared to have a viral hepatitis but in whom screening 
for known viral aetiologies was negative. Hepatitis C 
serological testing was not available routinely at the time 
of the study. There were no patients with hepatitis A and 
this may be because this disease normally is self limiting 
with full recovery so that patients with this diagnosis 
were not referred to a specialized unit. Three patients had 
hepatitis B as the cause for their acute liver failure. The 
remainder of the patients had an assortment of aetiologies 
including acute Budd-Chiari syndrome, other drug reactions 
and post partum liver failure.
The overall mortality rate for patients reaching grade IV 
coma of 73% was low but reflects that in this series 
treatment was by medical management and by transplantation, 
with those patients in what have been reported as the poor 
prognosis groups being considered for transplantation. Of 
the patients taking an overdose of paracetamol and reaching 
grade IV coma the 75% mortality represents a waste of 
usually young life. Until recently liver transplantation
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was not even considered in this group of patients because 
of the likelihood of further parasuicide attempts (Goldacre 
1985). Three of our patients in this group were placed on 
the list for emergency liver transplantation but only in 
one was this undertaken because of the nonavailability of 
donor organs. In this patient who was transplanted the 
operation was probably performed too late.
In the viral aetiology and other groups, the decision to 
proceed to transplantation was usually because of 
continuing deterioration in the patient's clinical state.
If a reliable method of identifying at the onset those 
patients who will not respond to medical management could 
be found this would help in the decision in whom and when 
to undertake liver transplantation.
O'Grady (1989) has published a new set of prognostic 
indicators which takes into account the underlying 
aetiology and gives an assessment on admission laboratory 
measurements and patient details. In this study's 
paracetamol group patients with an arterial blood pH <7.3, 
prothrombin time greater than 100 seconds and creatinine 
level above 300 have a poor prognosis. Our results would 
accord with this but in our patients a high admission 
bilirubin and being in coma on admission also have a poor 
prognosis. In O'Grady's study those patients at risk in the 
viral and other aetiologies group were aged less than 11 
years or over 40 years, were jaundiced for more than 7 days 
before the onset of encephalopathy, had an admission 
bilirubin greater than 300 and a prothrombin time above 50
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seconds. These factors were not significantly different 
between our survivors and non survivors. This difference 
may be a reflection of the numbers studied with many more 
patients over a longer time period in the Kings College 
Hospital series.
If these factors prove important in the prognosis of 
patients with fulminant liver failure they will be helpful 
in selecting patients who should be considered for 
transplantation. Even if this policy were to be followed 
there would still be a considerable number of patients who 
are at risk of dying from acute liver failure in whom 
transplantation would not be appropriate or for whom a 
donor liver could not be found. In these groups of patients 
there is a need for some other form of therapy to 
temporarily support the patient until the liver recovers.
Despite the reported successes of hepatocyte 
transplantation in the treatment of acute hepatic failure 
in laboratory animals (Sutherland 1977), the experiments 
reported here do not show any benefit to animal survival 
from hepatocyte transplantation by either the intrasplenic 
or the intraperitoneal route. This may have been because 
the model used was very severe with 100% mortality in the 
control animals. There were 2 survivors in the group of 
rats treated by intraperitoneal hepatocytes but the numbers 
studied were too small for any statistical difference to be 
demonstrated. In the spleens, of the intrasplenically 
injected rats at death, there were a few hepatocytes seen 
but there is no possibility that there was enough ectopic
117
liver tissue to function and keep the rat alive. Even the 
slightly more plentiful hepatocytes within the portal vein 
branches within the liver could not have been sufficient to 
maintain function.
In the rats which received intraperitoneal hepatocytes, 
hepatocytes were identified histologically in deposits 
within the peritoneal cavity and these had not been seen in 
experiments from other workers (Makowka 1980b, Sutherland 
1977). This may be because these rats only survived for 72 
hours after intraperitoneal injection of hepatocytes and 
that had the rat lived for longer these cells would have 
been destroyed. The implication of the presence of these 
cells and their possible future death could be important if 
it is accepted that intact hepatocytes are not responsible 
for improved survival in the animals with acute liver 
failure.
Since it has been shown by Makowka (1980c) that bone marrow 
cells are as effective as hepatocytes at treating acute 
liver failure in the experimental rat and by LaPlante 
O'Neill (1982) that the supernatant from hepatocyte 
cultures is equally effective, it is suggested that a 
substance from regenerating hepatocytes is what is 
producing the results seen. Further work implies that the 
substance(s) involved is organ specific but this does not 
explain the effect seen with bone marrow cells.
In the experiments described here attention was turned to 
the intracellular contents of the hepatocytes and a crude
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preparation of cytosol was produced by an alternative 
method. All previous work using cytosol had employed the 
homoginization of pieces of liver and then centrifugation 
of the homogenate with removal of the supernatant for use. 
This preparation must contain the same proportion of 
contents of cells as the cell populations in liver tissue,
i.e. approximately less than 70% hepatocytes and the other 
30-40% a mixture of Kupffer cells and endothelial cells 
(Daoust 1958). The cytosol used in the presented 
experiments was made by centrifugation of a suspension of 
isolated hepatocytes and therefore contains less than 5% of 
nonhepatocytes. This may account for some of the 
differences between the results presented here and other 
previously published findings.
When cytosol prepared from the hepatocytes of normal adult 
Wistar rats was injected intraperitoneally into rats which 
had toxin induced acute liver failure the treated rats had 
a significant improvement in survival with recovery to near 
normal liver histology. This finding is contradictory to 
the work of Schwarz (1985) who has reported that although 
cytosol from regenerating hepatocytes, either post 
hepatectomy or weanling livers, produces improved survival, 
cytosol from normal adult (nonregenerating) liver, if 
anything inhibits regeneration of hepatocytes, and is 
detrimental in the treatment of hepatic failure. The other 
major difference in the methodology of the present 
experiment is the dosage regime with the cytosol being 
given by repeated injections. This method of administration 
resulted in intraperitoneal haemorrhage in 2 of the treated
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rats and in 1 of the control group and it was therefore 
necessary to try a different route of administration which 
would be without this complication.
Since the cytosol did not contain any cellular particular 
matter it was thought that it could be given intravenously 
and for ease of administration a peripheral vein (tail 
vein) was chosen. If the factor responsible for the 
improved survival in the intraperitoneally injected rats 
was dependant on hepatotrophic factors produced within the 
nonhepatic splanchnic organs as work by Starzl (1980) had 
suggested, then peripherally administered cytosol might not 
be effective. The advisability of using this route would 
depend on whether the substance reached the liver or was 
metabolised or denatured in the lungs or other organs, 
whether it reached the liver in sufficient quantity 
considering the volume of distribution within the whole 
animal and if it was in fact acting directly upon the liver 
in the first place.
When the cytosol was given by repeated intravenous 
injection there was a marked improvement in survival with 9 
of the 12 treated rats recovering from acute hepatic 
failure. However, the mechanism remains unclear. Since 
Magee's experiments in 1956 showed that all the DMNA was 
removed from the rat by 4 hours after dosage, it is 
unlikely that the cytosol is mopping up the hepatotoxin 
since the first dose is given 6 hours after the induction 
of liver failure. Chemicals within the cytosol could be 
supporting the liver and reducing the amount of toxins
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which the liver is unable to metabolise circulating in the 
animal. This seems unlikely since this function should 
require intact functioning cells. It is more likely that a 
component of the cytosol stimulates regeneration of the 
remaining hepatocytes. This does not imply that it is 
acting directly upon the hepatic tissue but it could be 
producing its effect through another tissue or a 
hepatotrophic factor.
When the first dose of cytosol was given at 12 and 24 hours 
but not 30 hours after the induction of hepatic damage it 
was still effective at improving survival. If the recovery 
of the animals is due to stimulation of regeneration then 
it must be happening within the first 40 hours and 
initiated before 30 hours after the administration of DMNA.
The dosage of cytosol originally chosen was based on the 
number of hepatocytes usually transplanted (3-4 x 10? 
cells) (Sommer 1979) and so each dose of cytosol was 
equivalent to the contents of that number of cells. The 
cytosol was however thought to be going into a much larger 
volume of distribution. Different doses of cytosol were 
tried and the two lower doses showed no difference from the 
original dose in respect of rat survival.
To try to show if the rat recovery was due to regeneration 
rats were paired, one to receive cytosol and one saline, 
and when one of the pair died the other was sacrificed. All 
the rats died or were killed at 72 hours, and there was no 
significant difference in amount of hepatocyte necrosis but
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there was a significantly increased number of cells 
undergoing division in the cytosol treated rats. This 
suggested that cytosol was stimulating the hepatocytes to 
regenerate but the mechanism causing the increased 
regeneration and improved survival was not apparent.
y
Rat fresh frozen plasma did not improve the survival more 
than in the control group but neither was there a 
statistically proven difference between the survivals in 
the plasma and the cytosol treated groups. It is possible 
that if the liver is producing a substance which is capable 
of stimulating regeneration that this product could be 
secreted into the blood and be present in rat plasma*. 
Alternatively the protein in the plasma may be beneficial 
in a similar way to the administration of fresh frozen 
plasma in humans. The histological findings of increased 
cell division in the paired experiment would suggest 
however that the cytosol is doing more than just 
maintaining intravascular volume. If the number of rats had 
been larger in the plasma experiment comparing the results 
to cytosol and control groups the result might have been 
statistically different.
When cytosol prepared in the same way from human 
hepatocytes was administered in a similar manner to the rat 
model it produced a significant improvement in rat survival 
and its effect was the same as that seen for rat cytosol. 
The component of the cytosol which is producing this effect 
is therefore not species specific but is certainly present 
in both rat and human hepatocyte cytosol. Terblanche in
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1980 demonstrated that cytosol from regenerating dog liver 
was also effective at increasing liver regeneration.
The cytosol had been studied as a single entity but it is 
obviously a mixture of chemicals, mainly proteins, 
intracellular electrolytes with some electrolytes from the 
Hank's balanced salt solution in which the cells were 
suspended, and intracellular organelles. Attempts were made 
to try to characterise the active substance within the 
cytosol. Cytosol was heated at different temperatures for 
different times and none of the heated cytosols was 
effective at treating the acute liver failure in the animal 
model. The active component is therefore heat labile and 
could suggest that it is a peptide. When cytosol was 
dialysed across a small pore membrane against HESS so that 
components from the HESS would be retained but small 
molecules (smaller than 8,000 molecular weight) derived 
from the hepatocytes would be removed the modified cytosol 
was ineffective at treating acute hepatic failure. These 
findings suggested that the component of the crude cytosol 
which was responsible for the improvement in survival of 
the rat was a molecule of a size below 8,000 daltons and 
possibly below 6,000 daltons allowing for variations in the 
membrane.
To look for regeneration as shown by increased DNA 
synthesis the effect of cytosol added to rat hepatocytes in 
tissue culture was studied. The results of this series of 
experiments were difficult to interpret and this may be 
because of the different concentrations of cytosol used.
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The cells were all cultured under identical conditions and 
other than the timing variation introduced into the third 
experiment a standard method was used throughout. The 
overall suggestion was that the crude cytosol did not 
increase DNA synthesis and in some instances was either 
inhibitory to cell regeneration or was causing cell 
toxicity and death. The culture plates receiving cytosol 
showed a difference in the appearance of the cells with the 
hepatocytes appearing more spherical rather than the" 
flattened appearance seen in the control plates.
Undoubtedly some change was happening in the hepatocytes 
and they were not showing increased regeneration.
These tissue culture experiments might suggest that the 
effect of cytosol administered to the animal model was not 
brought about by increasing hepatocyte regeneration or it 
could be that the cytosol could only cause an increase in 
regeneration by synergism with or by acting upon another 
substance. The results in tissue culture did not suggest 
synergism with epidermal growth factor which is a known 
hepatotrophic growth factor. The cells in the tissue 
culture plates should be more than 95% pure hepatocytes 
whereas in the animal model the cytosol was circulating 
throughout the animal. This raises the possibility that the 
mechanism of action may be indirect through other tissues 
and the product of this interaction could then be 
stimulatory to the liver.
Previous work by Starzl (1980), mainly in the dog, 
suggested that the liver could only be stimulated in the
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presence of hepatotrophic factors derived from the 
nonhepatic splanchnic organs. In the dog with an Eck 
fistula if the extrahepatic organs including the pancreas 
and the spleen were removed the liver failed to regenerate. 
This was at the time attributed to substances from the 
pancreas (insulin and glucagon) being involved. This may be 
true but in the light of recent work with immunosuppressant 
agents it may have been an interaction with the 
reticuloendothelial system that is important.
Both cyclosporin (Kim 1988) and the new immunosuppressant 
FK506 (Francavilla 1989) have been shown to increase DNA 
synthesis in hepatocytes. The mechanism for this effect is 
as yet unknown but it has been suggested that the 
regeneration may be controlled or modified immunologically. 
It has been suggested that in normal situations the immune 
system limits cell growth but that this restricting effect 
is dependant on T cells whose function is inhibited by both 
FK506 and cyclosporin. It is possible that any 
immunological effect upon regeneration may also be operated 
by cytokines since both of the immunosuppressive drugs 
mentioned inhibit interleukin 2 production and function.
Any involvement of the action of cytosol with the immune 
system is purely supposition but it would explain the 
apparent discrepancy between the in-vivo results reported 
.here and those obtained from the in-vitro work.
Immunological stimulation could explain why the bone marrow 
cells transplanted by Makowka (1980c) were effective at 
treating rats with acute liver failure. Other workers
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reporting studies looking at liver regeneration consider 
the identified hepatotrophic factors to be organ specific 
and site as evidence the fact that liver cytosol does not 
produce proliferation in the kidney (Starzl 1980). A 
hepatolymphatic relationship in the control of liver 
regeneration was suggested by Sakai (1975) when he 
postulated that an observed breakdown of lymphocytes 7-8 
hours after partial hepatectomy might release a substance 
which was stimulatory to hepatocytes and lymphocytes. He 
showed also that partial hepatectomy reduces the 
recruitment of thymus cells but increases the number of B 
lymphocytes. Ohkawa in 1985 showed that regenerating rat 
liver cytosol improves reticuloendothelial function before 
it increases DNA synthesis supporting an immunologically 
mediated stimulus to liver regeneration.
Many substances have been suggested as hepatotrophic 
factors, some of which have been discounted but many have 
been identified, physically characterised, purified and the 
structure worked out. Proven factors stimulating liver 
regeneration include epidermal growth factor (EGF) (Cohen 
1974), hepatic stimulator substance (HSS) (LaBrecque 1985, 
1987, Francavilla 1988a), hepatocyte proliferation factor 
(HPF) (Schwarz 1985), hepatocyte proliferative stimulatory 
factor (HPSF) (Suemori 1988), transforming growth factor 
alpha (TGFa) (Fausto 1989, Tappin 1989), hepatopoietin A 
and hepatopoietin B (Michalopoulos 1984), liver growth 
factor (Diaz-Gil 1987), platelet associated factors (Strain 
1981), insulin and glucagon (Leffert 1980), oestrogen 
(Francavilla 1988b) and prolactin (Buckley 1988). Amongst
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these factors there is a marked similarity in size and 
three dimensional structure. Although some of them were 
originally described as larger molecules they have now been 
broken down and are now usually in the size range of 4,000 
to 8,000 daltons with the majority having a molecular 
weight of about 6,000. Some of these purified factors have 
been given in animal models of acute hepatic failure and 
have improved the survival of the animals (Francavilla 
1986).
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SUMMARY
Although liver transplantation has improved the survival 
from fulminant hepatic failure for selected patients it is 
unfortunately a remedy which is not appropriate or possible 
for all patients suffering from this disease. It also 
involves difficult surgery in a critically ill patient and 
commits the survivor to a life time of immunosuppression 
with all its inherent morbidity. Alternative methods of 
supporting the failed liver or increasing its rate of 
regeneration require to be found.
In the series of experiments presented in this thesis it 
has been found that a component of normal adult cytosol 
prepared from a suspension of isolated hepatocytes 
administered by repeated intravenous injections is able to 
improve the survival of rats with an otherwise fatal toxin 
induced hepatic failure. The active substance is present in 
both rat and human liver cytosol and is demonstrated to be 
a heat labile molecule with a molecular weight below 8,000. 
This substance gave results better than those obtained for 
hepatocyte transplantation in this model of liver failure. 
It seemed to increase hepatocyte regeneration in the* animal 
model but appeared to have no direct effect on liver 
regeneration when applied to hepatocytes in cell culture.
If this technique of intravenous administration of normal 
hepatocyte cytosol could be applied to humans it might 
improve the prognosis for some patients with fulminant 
liver failure.
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APPENDIX
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RAT USAGE
Rat No. Procedure
1. Blood sampling, liver and spleen histology-.
2. Blood sampling, unsuccessful liver perfusion
3. Hepatocyte isolation.
4. Hepatocyte isolation.
5. Hepatocyte isolation.
6. Hepatocyte isolation.
7. Hepatocyte isolation.
8. Induction of acute hepatic failure. DMNA 40mg/kg.
9. Induction of acute hepatic failure. DMNA 40mg/kg.
10. Induction of acute hepatic failure. DMNA 40mg/kg.
11. Hepatocyte isolation.
12. Induction of acute hepatic failure. DMNA 50mg/kg.
13. Induction of acute hepatic failure. DMNA 50mg/kg.
14. Induction of acute hepatic failure. DMNA 50mg/kg.
15. Induction of acute hepatic failure. DMNA 45mg/kg.
16. Induction of acute hepatic failure. DMNA 45mg/kg.
17. Induction of acute hepatic failure. DMNA 45mg/kg.
18. Hepatocyte isolation.
19. Induction of acute hepatic failure. DMNA 50mg/kg.
20. Induction of acute hepatic failure. DMNA 50mg/kg.
21. Induction of acute hepatic failure. DMNA 50mg/kg.
22. Induction of acute hepatic failure. DMNA 50mg/kg.
23. Induction of acute hepatic failure. DMNA 50mg/kg.
23(a) Hepatocyte isolation.
24. Acute hepatic failure, intrasplenic hepatocytes.
25. Acute hepatic failure, intrasplenic hepatocytes.
26. Died before hepatocytes given - discounted.
27. Hepatocyte isolation.
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28. Acute hepatic failure. intrasplenic hepatocytes.
29. Acute hepatic failure. intrasplenic hepatocytes.
30. Acute hepatic failure. intrasplenic hepatocytes.
31. Acute hepatic failure. intrasplenic hepatocytes.
32. Acute hepatic failure. intrasplenic hepatocytes.
33. Acute hepatic failure. intrasplenic hepatocytes.
34. Acute hepatic failure. intrasplenic hepatocytes.
35. Hepatocyte isolation.
36. Hepatocyte isolation.
37. Intrasplenic hepatocytes.
38. Intrasplenic hepatocytes.
39. Intrasplenic hepatocytes.
40. Intrasplenic hepatocytes.
41. Intrasplenic hepatocytes.
42. Acute hepatic failure. intrasplenic HESS.
43. Acute hepatic failure. intrasplenic HESS.
44. Acute hepatic failure. intrasplenic HESS.
45. Acute hepatic failure. intrasplenic HESS.
46. Acute hepatic failure. intrasplenic HESS.
47. Acute hepatic failure. IP hepatocytes
48. Acute hepatic failure. IP hepatocytes
49. Acute hepatic failure. IP hepatocytes
50. Acute hepatic failure. IP hepatocytes
51. Acute hepatic failure. IP hepatocytes
52. Hepatocyte isolation.
53. Acute hepatic failure. IP hepatocytes
54. Acute hepatic failure. IP hepatocytes
55. Acute hepatic failure. IP hepatocytes
56. Acute hepatic failure. IP hepatocytes
57. Acute hepatic failure. IP hepatocytes
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58. Hepatocyte isolation.
59. Acute hepatic failure, IP hepatocytes
60. Acute hepatic failure, IP hepatocytes
61. Acute hepatic failure, IP hepatocytes
62. Acute hepatic failure, IP hepatocytes
63. Acute hepatic failure, IP hepatocytes
64. Hepatocyte isolation.
65. Acute hepatic failure, IP hepatocytes
66. Acute hepatic failure, IP hepatocytes
67. Acute hepatic failure, IP hepatocytes
68. Acute hepatic failure, IP hepatocytes
69. Acute hepatic failure, IP hepatocytes
70. Hepatocyte isolation.
71. Hepatocyte isolation, cytosol production.
72. Hepatocyte isolation, cytosol production.
73. Acute hepatic failure, intraperitoneal cytosol
74. Acute hepatic failure, intraperitoneal cytosol
75. Acute hepatic failure, intraperitoneal cytosol
76. Acute hepatic failure, intraperitoneal cytosol
77. Acute hepatic failure, intraperitoneal cytosol
78. Acute hepatic failure, intraperitoneal cytosol
79. Acute hepatic failure.
80. Acute hepatic failure.
81. Acute hepatic failure, intraperitoneal cytosol
82. Acute hepatic failure, intraperitoneal cytosol
83. Acute hepatic failure, intraperitoneal cytosol
84. Acute hepatic failure, intraperitoneal cytosol
85. Hepatocyte isolation, cytosol production.
86. Acute hepatic failure.
87. Acute hepatic failure.
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88. Acute hepatic failure. intravenous cytosol.
89. Acute hepatic failure. intravenous cytosol.
90. Acute hepatic failure. intravenous cytosol.
91. Acute hepatic failure. intravenous cytosol.
92. Hepatocyte isolation. cytosol production.
93. Hepatocyte isolation. cytosol production.
94. Hepatocyte isolation. cytosol production.
95. Acute hepatic failure. intravenous cytosol.
96. Acute hepatic failure. intravenous cytosol.
97. Acute hepatic failure. intravenous cytosol.
98. Acute hepatic failure. intravenous cytosol.
99. Acute hepatic failure. intravenous cytosol.
100. Acute hepatic failure. intravenous cytosol.
101. Acute hepatic failure. intravenous cytosol
102. Acute hepatic failure. intravenous cytosol.
103. Acute hepatic failure. intravenous cytosol.
104. Acute hepatic failure. intravenous cytosol 12hr.
105. Acute hepatic failure. intravenous cytosol 12hr.
106. Acute hepatic failure. intravenous cytosol 12hr.
107. Acute hepatic failure. intravenous cytosol 6hr.
108. Acute hepatic failure. intravenous cytosol 6hr.
109. Acute hepatic failure. intravenous cytosol 6hr.
110. Acute hepatic failure. intravenous cytosol 24hr.
111. Acute hepatic failure. intravenous cytosol 24hr.
112. Acute hepatic failure. intravenous cytosol 24hr.
113. Hepatocyte isolation. cytosol production.
114. Hepatocyte isolation. cytosol production.
115. Hepatocyte isolation. heated cytosol production.
115(a) Heated cytosol production.
116. Acute hepatic failure.
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117. Acute hepatic failure.
118. Acute hepatic failure, IV heated cytosol.
119. Acute hepatic failure, IV heated cytosol.
120. Acute hepatic failure, IV heated cytosol.
121. Acute hepatic failure, intravenous cytosol.
122. Acute hepatic failure, intravenous cytosol-.
123. Acute hepatic failure, intravenous cytosol.
124. Acute hepatic failure, intravenous cytosol.
125. Acute hepatic failure, intravenous cytosol.
126. Hepatocyte isolation, dialysed cytosol.
127. Hepatocyte isolation, heated cytosol production
127(a) Heated cytosol production.
128. Acute hepatic failure. IV dialysed cytosol.
129. Acute hepatic failure. IV dialysed cytosol.
130. Acute hepatic failure. IV dialysed cytosol.
131. Acute hepatic failure. IV dialysed cytosol.
132. Acute hepatic failure. IV dialysed cytosol.
133. Acute hepatic failure. IV dialysed cytosol.
134. Acute hepatic failure. IV heated cytosol.
135. Acute hepatic failure. IV heated cytosol.
136. Acute hepatic failure. IV heated cytosol.
137. Acute hepatic failure. IV heated cytosol.
138. Acute hepatic failure. IV heated cytosol.
139. Acute hepatic failure. IV heated cytosol.
140. Acute hepatic failure.
141. Acute hepatic failure. IV cytosol 24 hrs.
142. Acute hepatic failure. IV cytosol 24 hrs.
143. Acute hepatic failure. IV cytosol 24 hrs.
144. Acute hepatic failure. IV cytosol 24 hrs.
145. Acute hepatic failure. IV cytosol 24 hrs.
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146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160. 
161. 
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
Acute hepatic failure. 
Acute hepatic failure, 
Acute hepatic failure. 
Acute hepatic failure. 
Acute hepatic failure. 
Acute hepatic failure. 
Plasma collection. 
Plasma collection. 
Plasma collection. 
Acute hepatic failure. 
Acute hepatic failure. 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure 
Acute hepatic failure
IV cytosol 30 hrs.
IV cytosol 30 hrs.
IV cytosol 30 hrs.
IV cytosol 30 hrs.
IV cytosol 30 hrs.
intravenous human cytosol, 
intravenous human cytosol, 
intravenous human cytosol, 
intravenous human cytosol 
intravenous plasma, 
intravenous plasma, 
intravenous plasma, 
intravenous plasma, 
intraperitoneal saline, 
intraperitoneal saline, 
intraperitoneal saline, 
intraperitoneal saline.
IV saline, 24hr sacrifice 
intravenous saline, 
intravenous cytosol, 
intravenous saline, 
intravenous cytosol, 
intravenous saline, 
intravenous cytosol.
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176. Acute hepatic failure, intravenous saline.
177. Acute hepatic failure, intravenous cytosol'.
178. Acute hepatic failure, intraperitoneal HESS.
179. Acute hepatic failure, intraperitoneal HESS.
180. Acute hepatic failure, intraperitoneal HESS.
181. Acute hepatic failure, intraperitoneal HESS.
182. Acute hepatic failure, IV saline, 30hr sacrifice
183. Hepatocyte isolation.
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HEPATOCYTE ISOLATION
Rat No H/C Viability Cells/ml Mis Tôt.cells Cytosols
3 H 72% 7.2x10^ 20 1.42x10^
4 H 80% 1.63x10? 20 3.26x10^
5 unsuccessful -
6 H 92% 4.9x10^
7 H 82% 1.12x10? 25 2.8x10^
11 H 75% 1.64x10? 25 4.1x10^
18 H 89% 2.56x10? 30 7.68x10^
23a H 85% 3.06x10? 20 6.12x10^
27 H 90% 2.78x10? 20 5.56x10^
35 H 74% 3.15x10? 20 6.3x10^
36 H 68% 2.86x10? 20 5.72x10^
52 H 83% 3.94x10? 20 7.88x10^
58 H 84% 4.12x10? 20 8.24x10®
64 H 78% 4.42x10? 20 8.84x10® '
70 H 84% 6.15x10? 20 1.23x10^
71 C 84% 4.85x10^ 20 9.7x10? 5.7x10®
72 C 87% 2.40x10? 42 1.0x10^ 3.06x10?
85 C 84% 3.59x10? 20 7.18x10® 3.34x10?
92 C 88% 3.28x10? 25 8.2x10® 3.42x10?
93 C 89% 2.55x10? 20 5.1x10® 1.02x10?
94 C 93% 3.25x10? 45 1.46x10^ 1.9x10?
113 C 89% 3.36x10? 25 8.4x10® 3.36x10?
114 C 88% 2.05x10? 37 7.6x10® 3.09x10?
115 C 80% 1.54x10? 20 3.09x10® 3.09x10?
115a C 88% 9.7x10^ 15 1.45x10® 2.9x10?
126 C 88% 2.95x10? 35 1.03x10^ 3.43x10?
127 C 89% 2.08x10? 30 6.22x10® 3.11x10?
127a C 91% 4.5x10^
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100 4.5x10® 4.5x10?
SURVIVAL AND PERCENTAGE OF LIVER NECROSIS
Rat no.
DMNA 40 rag/kg
8
9
10
survival (hrs)
sacrifice
48
sacrifice
% hepatocyte necrosis 
centre periphery
0
81
0
0
39
0
DMNA 50 mg/kg
12 48
13 48
14 48
97
88
93
36
53
29
DMNA 45 mg/kg
15
16 
17
sacrifice
122
sacrifice
0
49
0
0
49
0
DMNA 50 mg/kg
19 41
20 43
21 42
22 42
23 43
95
90
90
79
79
73
75
55
56 
53
AHF + IS hepatocytes
24
25
26 
28
29
30
31
32
33
34
48
48 
6
76
7
49 
65 
45 
60 
60
77
62
59 
0
90
60 
75
91 
72
49.
54
43
0
65
70
57
69
75
noAHF, IS hepatocytes
37
38
39
40
41
sacrifice
sacrifice
sacrifice
sacrifice
sacrifice
AHF + IS sham injection
42 48
43 48
44 24
45 48
46 48
80
73
75
92
76
60
60
76
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Rat no. survival (hrs) % hepatocyte necro
AHF
47
+ IP hepatocytes
48
centre
78
per
66
48 216 54 42
49 60 67 69
50 150 89 62
51 70 69 58
53 62 75 69
54 62 91 72.
55 71 70 57
56 48 87 77
57 48 82 63
59 48 78 62
60 48 77 51
61 84 72 71
62 84 77 46
63 63 79 48
65 70 77 63
66 54 65 53
67 39 62 45
68 44 61 51
69 46 72 64
AHF
73
+ IP cytosol (71) daily
73 68 40
74 100 62 61
AHF
75
+ IP cytosol (72) daily 
100 72 37
76 48 59 62
AHF + IP cytosol (72) every 2nd day
'
77 sacrifice 0 0
78 48 86 81
81 72 75 55
82 48 79 64
AHF + IP cytosol (72) every 3rd day
83 72 60 46
84 54 76 50
AHF
79
controls
72 62 33
80 95 55 48
86 72 74 51
87 90 40 25
116 72 64 55
117 48 87 44
155 72 60 34
156 72 70 52
AHF
88
+ IV cytosol (85) daily
sacrifice 0 0
89 sacrifice 0 0 '
90 sacrifice 0 0
91 sacrifice 0 0
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Rat no. survival (hrs)
AHF + IV cytosol (93) daily
95 sacrifice
96 120
97 sacrifice
% hepatocyte necrosis 
centre periphery
0
60
0
0
39
0
AHF + IV cytosol (94) daily
98 48
99 sacrifice
100 sacrifice
65
0
0
62
0
0
AHF + IV cytosol (92) daily
101 sacrifice
102 72
103 sacrifice
0
60
0
AHF + IV cytosol (94) daily after 12 hrs
104 sacrifice 0
105 sacrifice 0
106 sacrifice 0
AHF + IV cytosol (94) daily after 6 hrs
107 216 0
108 sacrifice 0
109 72 75
AHF + IV cytosol (94) daily after 24 hrs
110 72 39
111 sacrifice 0
112 sacrifice 0
0
60
0
0
0
64
54
0
0
AHF controls
116 72
117 48
64
87
55
44
AHF + IV heat treated cytosol daily
118
119
120
140
102
96
58
79
78
43
47
58
AHF + IV cytosol (113) daily
121 sacrificed
122 sacrificed
123 48
124 sacrificed
125 116
0
0
58
0
38
0
0
48
0
30
AHF + IV dialysed cytosol (126) daily
128 65 66
129 90 68
130 70 65
131 60 73
132 90 58
133 60 52
56
66
25
49
56
28
160
Rat no'. survival (hrs) % hepatocyte necr<
centre pe;
AHF + IV heated cytosol (127,127a) daily
134 56 50 52
135 60 78 80
136 96 49 38
137 65 72 32
138 120 62 38
139 75 48 42
AHF + IV cytosol (various) after 24t hrs and daily
141 48 78 70
142 sacrificed 0 0
143 140 19 8
144 55 62 72
145 60 54 51
AHF + IV cytosol (various) after 3C) hrs and daily
147 31 79 71
148 40 80 69
149 48 78 74
150 81 64 56
151 40 76 68
AHF + IV saline at 24 and 30 hours
140 40 81 65
146 30 58 54
AHF + IV human cytosol daily
157 sacrificed 0 0
158 sacrificed 0 0
159 75 55 50
160 116 68 27
AHF + IV plasma daily
161 sacrificed 0 0
162 44 76 74
163 sacrificed 0 0
164 44 75 64
AHF + IP saline daily
165 48 70 54
166 48 67 58
167 44 82 84
168 44 56 66
AHF + IV saline and sacrifice
169 24 63 57
182 30 62 52
AHF + IV saline daily
170 72 55 47
172 72 78 48
174 68 69 52
176 72 70 60
riphery
161
Rat no. survival (hrs) % hepatocyte necrosis
centre periphery
AHF + IV cytosol (various) daily and sacrifice 
171 72s 59 45
173 72s 44 54
175 72s 47 35
177 72 76 48
AHF + IP Hank's single
178 53 82 62"
179 57 70 69
180 44 70 58
181 72 52 69
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MITOTIC INDICES
AHF + IV saline and death
Rat no. mitotic figures total no. (
170 8 143
14 128
10 95
9 97
172 14 129
7 122
4 105
9 113
174 19 162
18 162
16 163
16 134
176 9 69
17 145
15 162
12 112
AHF + IV cytosol and sacrifice
Rat no. mitotic figures total no. (
171 18 112
14 101
13 105
18 110
173 13 107
11 100
13 83
11 103
175 21 151
10 95
10 84
12 83
177 19 146
20 112
16 120
16 128
of nuclei
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NORMOTEST RESULTS
DMNA 40 mg/kg
rat no. I
hours 0 50-
6 38!
24 21!
48 7!
72 31!
96 35!
120 31!
144 30!
192 42!
244 
292 
316
9
43!
35!
22!
18!
10
44%
42%
21%
12%
31%
47%
35%
39%
47%
70%
35%
50%
DMNA 50 mg/kg
rat no. 
hours 0
16 
28
12
50%
23%
13
45%
16%
<5%
14
54%
23%
<5%
DMNA 45 mg/kg 
rat no. 
hours 0 
23 
33 
48 
72 
105 
124 
151
15
41%
24%
<5%
<5%
62%
45%
54%
16
46%
10%
<5%
<5%
5%
22%
17
46%
<5%
<5%
<5%
<5%
34%
50%
50%
DMNA 50mg/kg
rat no. 19 20 21 22 23
hours 0 42% 46% 46% 42% 44%
18 6% 10% 7% 12% 18%
25 <5% <10% <5% <10%
42 <5% <5% <5% <5%
AHF + IS hepatocytes 
rat no 
hours
24 25 28 29
0 37% 29% 46% 64%
6 27% 29% 27% 70%
24 <5% <5% 9%
30 <10% <5%
48 <5% <5% <5%
56 <5%
72 <10%
164
hours
hours
hours
hours
hours
hours
hours
no. 30 31 32 33 34
0 35% 50% 46% 54% 70%
6 <5% 47% 20% 33% <5%
21 <5% <5% <5% 14% <5%
43 <5% <5% <5%
49 <5%
IS hepatocytes
no. 37 38 39 40 41
0 34% 38% 50% 45% 38%
20 30% 35% 25% 27% 45%
45 32% 50% 40% 100% 64%
68 54% 31% 40% 41% 34%
121 34% 50% 34% 34% 27%
164 31% 76% 86% 50% 50%
210 50% 58% 64% 64%
259 58% 64% 76%
308 • 46% 45%
356 46%
IS :sham injection
no. 42 43 44 45 46
0 54% 86% 45% 54% 63%
6 70% 50% 54% 78% 63%
24 31% 6% 9% <5%
IP :hepatocytes
no. 47 48 49 50 51
0 31% 39% 54% 39% 76%
6 41% 58% 54% 56% 54%
30 <5% 9% <5% 7% <5%
48 <5% <10% <5% <10%
72 6% <5%
150 47% 41%
216 62%
no. 53 54 55 56 57
0 37% 45% 32% 42% 46%
6 47% 50% 32% 64% 34%
25 <10% <10% <10% <10%
48 <10% <10% <5% <5%
no. 59 60 61 62 63
0 53% 50% 39% 60% 60%
6 41% 34% 46% 46% 37%
24 <10% 7% 10% 10% 5%
48 <5% <5% <10% <5% <10%
no. 65 66 67 68 69
0 36% 58% 42% 70% 39%
6 53% 20% 31% 25% 34%
24 9% <10% <5%
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AHF + IP cytosol (71) daily
rat no. 73 74
hours 0 31% 41%
6 70% 50%
24 9% 10%
72 <10% <10%
96 <10%
AHF + IP cytosol (72) daily
rat no. 75 76
hours 0 30% 29%
6 21% 35%
24 7% 9%
48 10%
AHF + IP cytosol (72) every 2nd day
rat no. 77 78 81 82
hours 0 35% 33% 34% 41%
6 35% 32% 35% 14%
24 8% <5% 5% <10%
48 5% <10% <5%
72 <5%
96 13%
148 22%
194 14%
240 70%
336 39%
AHF + IP cytosol (72) every 3rd day
rat no. 83 84
hours 0 76% 46%
6 58% 24%
25 <5% 8%
48 <10% <10%
AHF control
rat no. 79 80 86 87
hours 0 35% 47% 44% 63%
6 31% 10% 28% 31%
24 <10% <10% <10% 14%
48 <10% <10% <10% 13%
AHF + IV cytosol (85) daily
rats1 no. 88 89 90 91
hours 0 53% 44% 46% 58%
6 35% 44% 35% 39%
24 9% 24% 21% 18%
48 9% <10% <5% <10%
72 24% 21% 8% 15%
100 24% 16% 24% 29%
144 37% 41% 41% 47%
196 39% 41% 41% 27%
630 64% 70% 76% 76%
166
AHF + IV cytosol (93) daily
hours
hours
hours
hours
hours
no. 95 96 97
0 31% 37% 44%
6 41% 50% 44%
24 12% 18% 16%
48 9%
96 35% <5% 44%
120 44% 44%
168 35% 32%
533 50% 44%
IV cytosol (94) daily
no. 98 99 100
0 41% 39% 41%
6 12% 35% 47%
24 11% 13% 18%
48 7% 7%
72 20% 26%
96 35% 46%
120 35% 39%
168 44% 39%
533 50% 50%
IV cytosol (92) daily
no. 101 102 103
0 41% 44% 32%
6 44% “ 50% 30%
24 16% 14% 16%
48 14% <5% 9%
72 25% 18%
96 41% 41%
120 44% 37%
168 50% 39%
533 47% 44%
IV cytosol (94) daily after 12 hrs
no. 104 105 106
0 34% 22% 30%
12 18% <5% 17%
24 <5% 6% <5%
48 21% <5% <5%
72 30% 39%
96 20% 5% 28%
144 39% 31% 26%
216 96% 44% 47%
365 54% 50% 50%
IV ,cytosol (94) daily after 6 hrs
no. 107 108 109
0 41% 37% 29%
6 25% 41% 50%
24 <5% <5% <5%
48 <5% <5%
72 12%
96 37% 31%
144 44% 32%
216 47% 70%
365 70%
167
AHF + IV cytosol (94) daily after 24 hrs
rat no. 110 111 112
hours 0 50% 47% 58%
24 <5% <5% <5%
48 29% 8%
72 53% 39%
96 34% 41%
144 44% 39%
216 47% 47%
365 54% 58%
AHF control
rat no. 116 117
hours 0 35% 43%
6 25% 27%
24 <5% <5%
48 <5%
AHF + IV heat treated cytosol daily
rat no. 118 119 120
hours 0 37% 46% 60%
6 22% 23% 33%
24 <5% <5% <5%
48 <5% <5%
72 10%
102 23% 5%
AHF + IV cytosol (113) daily
rat no. 121 122 123 124
hours 0 48% 46% 43% 31%
6 25% 27% 31% 45%
24 <5% 14% <5% <5%
48 <5% <5%
72 18% 6% <5%
102 40% 9% 26%
144 18% 20% 30%
192 20% 20% 18%
365 51% 48% 48%
125
48%
30%
6%
<10%
18%
AHF + IV dialysed cytosol (126) daily
rat no. 128 129 130 131 132 133
hours 0 29% 20% 43% 26% 39% 33%
6 45% 34% 43% 43% 23% 11%
24 6% <5% 9% 11%
48 <5%
72 <5%
AHF + IV heated cytosol (127,127a) daily
rat no. 134 135 136 137 138 139
hours 0 29% 36% 43% 36% 29% 25%
6 34% 39% 54% 37% 43% 37%
24 <10% <5% 8% <5% 7% 12%
48 <5% <5% <5%
72 5% <5%
168
AHF + IV cytosol (various) after 24 hrs and daily
rat no. 141 142 143 144
hours 0 70% 43% 35% 64%
24
48 <5% <10% <5%
72 27%
96 29% 6%
168 35%
216 39%
312 43%
360 70%
AHF + IV cytosol (various) after 30 hrs and daily
rat no. 147 148 149 150
hours 0 41% 34% 64% 43%
30 <5%
48 <5%
AHF + IV saline
rat no. 140 146 155 156
hours 0 51% 39% 29% 33%
6 29% 30%
24 19% 6% 9%
30 <5%
48 <5%
72 16% <5%
AHF + IV :human cytosol
rat no. 157 158 159 160
hours 0 21% 31% 34% 76%
6 36% 33% 27% 26%
24 <5% 6% 11% 10%
48 <5% <5% <5%
72 9% 6% <5% <5%
96 43% 24% <5%
144 24% 27%
192 20% 29%
312 31% 34%
388 36% 39%
AHF + IV plasma daily
rat no. 161 162 163 164
hours 0 43% 48% 43% 31%
6 30% 34% 59% 20%
24 <5% 15% 12%
72 12%
96 33% 29%
144 34% 26%
192 28% 34%
312 31% 39%
388 43% 39%
AHF + IP saline daily
rat no. 165 166 167 168
hours 0 37% 70% 37% 39%
6 28% 36% 29% 33%
24 10% 6% 11% <5%
48 <5% <5%
145
31%
13%
<5%
151
58%
169
AHF + IV saline and sacrifice
rat no. 169 182
hours 0 37% 46%
6 36% 51%
24 <5% <5%
30 <5%
AHF + IV saline
rat no. 170 172 174 176
hours 0 36% 37% 39% 39%
6 31% 36% 33% 29%
24 13% 13% 5% <5%
48 <5%
72 <5% <5% <5%
AHF + IV cytosol (various) and sacrifice
rat no. 171 173 175 177
hours 0 34% 37% 41% 39%
6 31% 36% 55% 36%
24 10% 10% 6% <5%
48 <5% <5%
72 <5% <5% 7%
AHF + IP Hanks single
rat no. 178 179 180 181
hours 0 41% 37% 39% 20%
6 37% 55% 43% 31%
24 7% <5% <5%
48 <5% <5% <5%
72 <5%
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ALT RESULTS
DMNA 40 mg/kg
rat no. 8
hours 0 100
6 40
24 51
48 300
72 869
96 427
120 214
144 99
192
292
316
74
DMNA 50 mg/kg
rat no. 12
hours 0 88
16 154
28 2004
DMNA 45 rag/kg
rat no. 15
hours 0
23
48
105
124
151 64
9
103
74
91
2626
13
35
114
597
16
54
1038
252
10
100
71
141
1000
357
155
96
88
91
65
14
40
329"
591
17
61
1340
197
77
37
DMNA 50 mg/kg
rat no. 
hours 0 
18 
25 
42
19
49
20
60
1008
328
21
67
2934
2353
22
52
668
2679
72
23
54
257
561
AHF + IS hepatocytes 
rat no. 24
hours 0 43
6
48
76
rat no. 
hours 0 
6 
21 
43 
49 
65
315
30
53
975
25
91
725
28
132
127
560
31
40
48
4157
32
50
2673
33
239
4062
29
67
no-
34
58
4290
171
noAHF, IS hepatocytes
rat no. 37 38 39 40 41
hours 0 55 53 70 51 72
20 553 313 277 962
45 184 90 222
68 92 105 90 89
121 54 54 48 49
164 46 91 39 54 58
210 35 59 39 62
259 39 50 50
308 41 51
356 42
AHF + IS sham injection
rat no. 42 43 44 45 46
hours 0 42 42 44 51 45
6 57 36 85 51 35
24 694 2136
48 4660 6789 7558
AHF + IP hepatocytes
rat no. 47 48 49 50 51
hours 0 49 32 44 39 76
6 32 26 35 38 52
30 3950 2750
48 2040
70 2715
150 84 112
216 29
rat no. 53 54 55 56 57
hours 0 56 68 73 54 54
6 48 76 59 35 97
69 280
rat no. 59 60 61 62 63
hours 0 75 64 65 51 52
6 63 63 47 44 37
24 1185 717 5128
48 3525 5805 185
rat no. 65 66 67 68 69
hours 0 69 119 55 26 21
6 123 120 34 8640
24 11480 7116
39 49
45 17 2050
54 900
70 2100
AHF + IP cytosol (71) daily
rat no. 73 74
hours 0 92 112
24 728 1540
72 910
100 25
172
AHF + IP cytosol (72) daily
rat no. 75 76
hours 0 135 136
6 95
24 6705 2600
48 3705
100 187
AHF + IP cytosol (72) every 2nd day
rat no. 77 78
hours 0 125
6 77
25 9460
48 8280
72
148 152
AHF + IP cytosol (72) every 3rd day
rat no. 83 84
hours 0 84 75
6 70
54 2810
72 304
AHF control
rat no. 79 80
hours 0 112 90
6 68
24
48
72 2360
90 117
AHF + IV cytosol (85) daily
rat no. 88 89
hours 0 69 68
6 56 56
24 3051 576
48 3270
72 1008 2114
100 294 516
144 88 130
196 84 100
630 54 96
81
150
115
721
1390
86
64
42
90
72
56
1190
580
99
89
78
82
76
76
48
87
60
45
462
6040
91
65
60
1932
608
153
111
102
AHF + IV cytosol (93) daily
rat no 
hours 0
6
24
96
120
168
533
95
100
80
775
332
94
96
84
70
625
1030
1848
97
80
68
1169
852
336
100
101
173
AHF + IV cytosol (94) daily
rat no. 98 99 100
hours 0 84 80 70
6 70 60 40
24 1784 475 390
48 4040 4760 4140
72 1948 1482
96 830 665
120 245 160
168 65 105
533 112 129
AHF + IV cytosol (92) daily
rat no. 101 102 103
hours 0 92 80 80
6 56 70
24 785 500 840
48 5180 4680
72 2590 1425 1940
96 1062 955
120 356 380
168 120 133
533 108 120
AHF + IV cytosol (94) daily after 12 hrs
rat no. 104 105 106
hours 0 175 128 168
12 136
24 4410
48 2208 2073 2320
72 706
96 355 305
144 120 120 96
216 110 126 126
365 132 142 150
AHF + IV cytosol (94) daily after 6 hrs
rat no. 107 108 109
hours 0 140 279 148
6 111 95
24 4312
72 3165
96 575 152
144 140 135
216 160 184
365 142
AHF + IV cytosol (94) daily after 24 hrs
rat no. 110 111 112
hours 0 130 120 138
24 4212 4896
48 1833 3101
72 532 834
96 261 380
144 84 240
216 144 160
365 133 118
174
AHF control 
rat no. 
hours 0 
6 
24 
48 
70
116
145
280
117
75
65
3450
858
AHF + IV heat treated cytosol daily
rat no. 118 119 120
hours 0 119 70 95
6 80 60 65
24 1449 4949 3855
72 1770
96 116
102 415
AHF + IV cytosol (113) daily
rat no. 121 122 123 124 125
hours 0 100 99 85 70 70
6 84 70 60 75 63
24 1255 504 3945 2562
48 4020
102 300 645
144 100 120 125
192 65 66 77
365 78 104 92
AHF + IV dialysed cytosol (126) daily
rat no. 128 129 130 131 132 133
hours 0 88 66 91 70 63
6 95 60 105 121
24 749 465
60 1065 3157
65 3024
70 82
90 24 '
AHF + IV heated cytosol (127,127a) daily
rat no. 134 135 136 137 138 139
hours 0 55 96 65 84 50 85
6 35 90 49 75 75 77
24 2211 4191 511
56 568
60 2605
65 641
75 615
96 250
120 34
175
AHF + IV cytosol (various) after 24 hrs and daily
rat no. 141 142 143 144 145
hours 0 90 80 85 70 75
24 1330
48 19
55 3865
60 4932
168 70
216 90
312 135
360 105
AHF + IV cytosol (various) after 30 hrs and daily
rat no. 147 148 149 150 151
hours 0 75 91 95 95 84
30 5985
40 6423 - 9828
48 2885
81 22
AHF + IV saline
rat no. 140 146 155 156
hours 0 85 65 84 50
6 65 35
24 1115 3960 300
30 4920
40 7500
48 2720
72 15 722
AHF + IV human cytosol
rat no. 157 158 159 160
hours 0 90 40 85 75
6 65 49 50 75
24 780 1106 330 1245
48 4664
72 1603 83
96 835 715 1310
116 1672
144 135 155
192 145 95
312 133 110
388 136 122
AHF + IV plasma daily
rat no. 161 162 163 164
hours 0 65 132 85 90
6 65 56 60 70
24 5698 378 250
44 5680 6068
96 492 400
144 90 80
192 95 110
312 120 98
388 118 116
176
AHF + IP saline daily
rat no. 165 166 167 168
hours 0 90 85 70 75
6 70 56
24 1309 2354 1030
44 3508
48 270 158
AHF + IV saline and sacrifice
rat no. 169 182
hours 0 80 77
6 65 49
24 16 2057
30 4372
AHF + IV saline
rat no. 170 172 174 176
hours 0 75 50 55 70
6 60 45 50 45
24 615 825 400 2545
72 22 43 4345 198
AHF + IV cytosol (various) and sacrifice
rat no. 171 173 175 177
hours 0 50 39 90 55
6 45 55 75 51
24 845 885 3555
48 4600
72 18 519 4355
AHF + IP Hanks single
rat no. 178 179 180 181
hours 0 105 95 70 45
6 75 75 65 56
24 3360
48 6332
53 3445
57 3570
72 229
177
AST RESULTS
DMNA 40 rag/kg
rat no. 
hours 0 
6 
24 
48 
72 
96 
120 
144 
192 
292 
316
8
210
99
223
785
2002
857
441
193
97
9
230
139
321
10019
10
237
147
357
1498
495
206
142
104
201
89
DMNA 50 rag/kg
rat no. 
hours 0 
16 
28
12
164
491
3200
13
113
431
2110
14
155
893
2575
DMNA 45 mg/kg
rat no. 
hours 0 
23 
48 
105 
124 
151
15 16
104
1904
293
167
17
109
2191
283
134
88
DMNA 50 rag/kg
rat no. 
hours 0 
18 
25 
42
19
94
20
82
990
6919
21
95
2110
10870
22
122
952
6985
8900
23
92
282
11264
AHF + IS hepatocytes
rat no. 24 25 28 29
hours 0 95 86 86 62
6 610 170 165 110
48 5907 5214
76 3049
rat no. 30 31 32 33 34
hours 0 222 70 96 82 60
6 180 132 162 150
21 4098
43 10131 11385
49 6292
65 9196 9185
178
noAHF, IS hepatocytes
hours
no. 37 38 39 40 41
0 136 100 100 94 92
20 841 622 509 1526
45 320 172 480
68 290 391 229 158
121 153 137 79 74
164 107 265 84 176 124
210 91 153 91 195
259 96 180 133
308 80 104
356 107
AHF + IS sham injection
rat no. 42 43
hours 0 107 199
6 244 142
24 1387
48 17168 11133
AHF + IP hepatocytes
rat no. 47 48
hours 0 194 70
6 130 174
30 7150
48 10310
60
70
150 282
216 92
rat no. 53 54
hours 0 222 183
6 170 258
48
69
rat no. 59 60
hours 0 245 420
6 170 318
24
48 15630 19140
87
rat no. 65 66
hours 0 207 440
6 410
24
39
45
54 11820
70 9300
44
216
389
45
111
157
46
212
111
49
110
354
8520
55
215
246
5190
61
303
174
1540
5450
67
170
410
145
50
86
222
3470
357
56
188
100
12915
62
145
124
1032
3100
68
140
122
51
250
117
8100
57
225
318
9705
63
172
135
9000
5130
- 69 
312 
12270 
9860
11940
AHF + IP cytosol (71) daily
rat no. 73 74
hours 0 116 136
24 763 1060
72 2060
100 1189
179
AHF + IP cytosol (72) daily
rat no. 75 76
hours 0 120 200
6 145
24 4490 2060 -
48 9915
100 1020
AHF + IP cytosol (72) every 2nd day
rat no. 77 78 81 82
hours 0 125 145 204
6 238 150 230
25 7320 917
48 17120 7280
72 5150
148 304
AHF + IP cytosol ( 72) every' 3rd day
rat no. 83 84
hours 0 244 170
6 245
54 8275
72 4200
AHF control
rat no. 79 80 86 87
hours 0 232 255 96 130.
6 224 133 120
24 651
48 8500
72 9850
90 1619
AHF + IV cytosol (85) daily
rat no. 88 89 90 91
hours 0 132 100 92 100
6 136 126 112 115
24 3984 920 1920 2376
48 7885
72 1352 2345
100 427 648 664 836
144 168 195 135 192
196 160 220 111 195
630 80 116 80 102
AHF + IV cytosol (93) daily
rat no. 95 96 97
hours 0 225 184 205
6 115 115 152
24 760 745 1169'
96 1800 740
120 336 2345 364
168 350
533 88 125
180
AHF + IV cytosol (94) daily
rat no. 98 99 100
hours 0 152 110 168
6 161 110 96
24 1656 655 630
48 8860 7828 8032
72 2340 1912
96 990 860
120 495 215
168 115 285
533 94 106
AHF + IV cytosol (92) daily
rat no. 101 102 103
hours 0 216 160 305
6 108 125
24 865 715 910
48 8583
72 2675 2010 1950
96 1044 930
120 375 445
168 240 580
533 98 108
AHF + IV cytosol (94) daily after 12 hrs
rat no. 104 105 106
hours 0 295 188 180
12 312
24 6090
48 2859 2421 2540
72 852
96 385 365
144 150 175 92
216 244 150 162
365 160 125 120
AHF + IV cytosol (94) daily after 6 hrs
rat no. 107 108 109
hours 0 200 396 248
6 180 155
24 4704
72 3000
96 610 508
144 195 261
216 394 332
365 187
AHF + IV cytosol (94) daily after 24 hrs -
rat no. 110 111 112
hours 0 125 116 168
24 7016 6813
48 2373 5481
72 835 844
96 333 516
144 108 510
216 177 225
365 101 132
181
AHF control 
rat no 
hours
rat no 
hours
116 117
0 275 180
6 190
24 3055
48 9300
70 4164
heat treated cytosol daily
118 119 120
0 350 147 190
6 180 140 170
24 1827 6027 5120
72 1835
96 1690
102 500 2061
AHF + IV cytosol (113) daily
hours
no. 121 122
0 140 186
6 182 135
24 1560 819
48
102 375
144 170 207
192 155 111
365 114 104
123
565
160
7500
AHF + IV dialysed cytosol (126) daily
rat no. 128 129 130 131
hours 0 132 242 175 133
6 170 135
24 1043
60 6650
65
70
90
8561
4415
908
AHF + IV heated cytosol (127,127a) daily
rat no. 
hours 0 
6 
24 
56 
60 
65 
75 
96 
120
134
136
110
4755
135
138
145
8595
136
135
154
137
120
95
2563
4210
967
124 125
505 75
215 210
4200 3486
740
275
126
92
132 133
126
203 220
645
10234
2916
138 139
80 80
145 525
4653 602
3970
989
182
AHF + IV cytosol (various) after 24 hrs and daily
rat no. 141 142 143 144
hours 0 460 280 140 120
24
48 7595
55 11240
60
168 85
216 155
312 95
360 85
AHF + IV cytosol (various) after 30 hrs and daily
rat no. 147 148 149 150
hours 0 330 133 245 465
30 6525
40 13524
48 7500
81 2016
AHF + IV saline
rat no. 140 146 155 156
hours 0 225 385 364 150
6 120 112
24 1355 3430 620
30 10290
40 7500
48 4890
72 1345 1786
AHF + IV human cytosol
rat no. 157 158 159 160
hours 0 185 155 190 240
6 150 203 135 140
24 1005 1050 390 1175
48 5797
72 1498 4755
96 825 640 1300
116 2164
144 115 125
192 195 105
312 125 100
388 84 108
AHF + IV plasma daily
rat no. 161 162 163 164
hours 0 140 209 235 145
6 120 105 110 150
24 4378 749 415
44 6000 6000
96 513 750
144 95 140
192 85 120
312 85 70
388 76 88
145
405
1540
13130
151
105
13566
183
AHF + IP saline daily
rat no. 165 166 167 168
hours 0 100 225 305 145
6 125 84
24 1330 3157 1250
44 6120
48 5670 10055
AHF + IV saline and sacrifice
rat no. 169 182
hours 0 355 175
6 180 154
24 2728
30 7292
AHF + IV saline
rat no. 170 172 174 176
hours 0 210 145 110 125
6 145 115 100 126
24 972 1000 6665 2310
72 3085 9945 3357
AHF + IV cytosol (various) and sacrifice
rat no. 171 173 175 177
hours 0 120 120 395 135
6 120 150 145 108
24 1550 1275 3430
48 4850
72 2562 2985 2176 4530
AHF + IP Hanks single
rat no. 178 179 180 181
hours 0 105 510 390 380
6 110 145 120 175
24 2965
48 6000
53 7500
57 10530
72 1913
184
ALKALINE PHOSPHATASE RESULTS
DMNA 40 mg/kg
rat no. 8
hours 0 426
6 271
24 440
48 330
72 720
96 699
120 754
144 797
192 550
292 
316
9
365
536
414
683
10
396
490
472
672
907
692
538
450
554.
536
DMNA 50 mg/kg
rat no. 
hours 0
16 
28
12
212
312
435
13
527
323
420
14
481
343
491
DMNA 45 mg/kg
rat no. 
hours 0
23 
48 
105 
124 
151
15 16
398
417
884
578
17
388
346
664
587
460
DMNA 50 mg/kg
rat no. 
hours 0 
18 
25 
42
19
172
20
221
348
551
21
362
742
657
22
232
189
184
500
23
241
643
409
AHF + IS hepatocytes 
rat no. 24
hours 0 360
6
48 567
76
25
576
621
28
750
148
709
29
513
247
rat no. 
hours 0 
6 
21 
43 
49 
65
30
170
498
31
295
188
1211
32
202
749
33
250
34
327
831
761
185
noAHF, IS hepatocytes
hours
AHF +
hours
hours
hours
hours
hours
no. 37 38 39 40 41
0 488 329 422 314 378
20 363 438 567 536
45 400 294 436
68 284 141 132 360
121 336 282 315 327
164 537 410 318 318 465
210 389 372 360 312
259 450 294 495
308 385 530
356 360
IS sham injection
no. 42 43 44 45 46
0 360 358 555 372 309
6 147 252 198 236 231
24 204 408
48 530 490 617 695
IP hepatocytes
no. 47 48 49 50 51
0 417 390 456 350 320
6 188 285 213 100 375
30 531 308
48 480
70 747
150 606 1644
216 442
no. 53 54 55 56 57
0 603 852 460 505 297
6 430 546 180 390 279
48 519 580
69 836
no. 59 60 61 62 63
0 510 545 384 575 392
6 415 204 327 385 440
24 525 417 605
48 809 751 653
87 2380
no. 65 66 67 68 69
0 441 270 455 304 308
6 245 675 290 706 264
24 225 507
39 503
45 709 591
54 670
70 683
AHF + IP cytosol (71) daily 
rat no. 73
hours 0 328
24 252
72 509
100
74
308
360
492
186
AHF + IP cytosol (72) daily
rat no. 75 76
hours 0 355 48
6 180
24 370 490
48 417
100 404
AHF + IP cytosol (72) every 2nd day
rat no. 77 78 81 82
hours 0 440 300 372
6 308 270 225
25 464 378
48 537 639
72 465
148 708
AHF + IP cytosol (72) every 3rd day
rat no. 83 84
hours 0 308 430
6 145
54 498
72 556
AHF control 
rat no 
hours
hours
79 80 86 87
0 344 345 692 630
6 304 511 490
24 700
48 660
72 710
90 349
cytosol (85) daily
88 89 90 91
0 666 696 768 620
6 504 518 472 515
24 549 712 786 636
48 740
72 1240 1057
100 1323 1407 1312 1184
144 728 945 921 1041
196 712 1764 819 774
630 378 452 510 460
AHF + IV cytosol (93) daily
rat no. 95 96 97
hours 0 380 564 415
6 405 470 372
24 525 570 378
96 920 912
120 1080 711 900
168 295
533 403 503
187
AHF + IV cytosol (94) daily
rat no. 98 99 100
hours 0 516 335 371
6 301 390 364
24 656 545 445
48 630 832 724
72 992 928
96 1095 1370
120 740 790
168 420 65
533 383 395
AHF + IV cytosol (92) daily -
rat no. 101 102 103
hours 0 308 445 445
6 364 380
24 400 615 420
48 651 744
72 835 785 835
96 924 1095
120 725 995
168 168 301
533 374 398
AHF + IV cytosol (94) daily after 12 hours
rat no. 104 105 106
hours 0 565 624 668
12 600
24 740
48 1008 942 935
72 1020
96 1180 995
144 585 755 548
216 296 590 1032
365 612 537 543
AHF + IV cytosol (94) daily after 6 hrs
rat no. 107 108 109
hours 0 630 540 484
6 534 590
24 700
72 902
96 1060 1196
144 865 666
216 420 468
365 529
AHF + IV cytosol (94) daily after 24 hrs
rat no. 110 ill 112
hours 0 640 616 672
24 820 774
48 852 770
72 938 1088
96 906 1174
144 528 615
216 486 590
365 575 509
188
AHF control
rat no. 116 117
hours 0 430 435
6 255
24 280
48 528
70 876
AHF + IV heat treated cytosol daily
rat no. 118 119 120
hours 0 539 546 400
6 315 320 180
24 785 560 460
72 785
96 456
102 810 1221
AHF + IV cytosol (113) daily
rat no. 121 122 123 124 125
hours 0 415 300 345 505 385
6 280 300 300 90 336
24 470 231 545 511
48 724
102 815 790
144 735 675 570
192 240 381 469
365 452 424 552
AHF + IV dialysed cytosol (126) daily
rat no. 128 129 130 131 132 133
hours 0 374 253 245 350 210
6 285 285 182 440
24 252 240
60 357 581
65 434
70 526
90 518 522
AHF + IV heated cytosol (127, 127a) daily
rat no. 134 135 136 137 138 139
hours 0 290 356 320 312 275 330
6 165 225 7 215 210 224
24 352 253 210
56 544
60 595
65 311
75 395
96 636
120 722
189
AHF + IV cytosol (various) after 24 hrs and daily
rat no. 141 142 143 144
hours 0 330 290 385 350 -
24
48 498
55 794
60
168 410
216 360
312 390
360 452
AHF + IV cytosol (various) after 30 hrs and daily
rat no. 147 148 149 150
hours 0 310 462 425 395
30 380
40 693
48 583
81 601
AHF + IV saline
rat no. 140 146 155 156
hours 0 380 225 301 245
6 310 224
24 385 450 335
30 370
40 624
48 460
72 524 506
AHF + IV human cytosol
rat no. 157 158 159 160
hours 0 385 430 295 265
6 310 301 340 335
24 215 336 385 335
48 297
72 462 458
96 570 725 1265
116 1010
144 480 585
192 340 390
312 490 430
388 450 464
AHF + IV plasma daily
rat no. 161 162 163 164
hours 0 345 649 470 535
6 325 483 365 355
24 198 420 360
44 862 798
96 879 540
144 670 365
192 510 385
312 545 399
388 558 430
145
240
310
708
151
420
723
190
AHF + IP saline daily
rat no 
hours 0
6
24
44
48
165
545
370
630
500
166
520
286
527
AHF + IV saline and sacrifice
rat no. 
hours 0
6 
24 
30
AHF + IV saline
rat no. 170
hours 0 345
6 285
24 336
72 432
AHF + IV cytosol
rat no. 
hours 0
6 
24 
48
72 206
169
415
215
454
172
310
210
320
575
167
455
345
620
182
273
84
88
438
174
235
185
380
865
(various) and sacrifice 
171 173 175
400 303 250
305 315 290
355 365
AHF + IP Hanks single
rat no 
hours 0
6
24
48
53
57
72
178
430
370
553
461
179
365
230
30
618
560
180
285
290
528
168
550
441
17
176
290
237
459
177
330
282
365
545
1480
181
365
147
578
191
BILIRUBIN RESULTS
DMNA 40rag/kg
rat no.
hours 0
6
24
48
72
96
120
144
196
292
316
8
10
10
10
10
10
10
10
10
10
9
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
DMNA 50mg/kg
rat no. 
hours 0
16 
28
12
10
10
22
13
10
10
43
14
10
10
55
DMNA 45mg/kg
rat no. 
hours 0
23 
48 
105 
124 
151
15 16
10
10
10
10
17
10
10
10
10
10
DMNA 50mg/kg
rat no. 
hours 0 
18 
25 
42
19
10
20
10
10
31
21
10
10
10
22
10
10
10
38
23
10
10
30
AHF + IS hepatocytes 
rat no. 24
hours 0 10
6 10
48 22
72
25
10
28
10
10
38
29
10
10
rat no 
hours 0
6
21
43
49
65
30
10
10
27
31
10
10
22
32
10
10
10
33
10
10
20
34
10
10
30
192
noAHF, IS hepatocytes
rat no. 37 38 39 40 41
hours 0 10 10 10 10 ' 10
20 10 10 10 10
45 14 10 10
68 10 10 10 13
121 10 11 10 10
164 10 10 10 10 10
210 10 10 16 10
259 10 10 10
308 10 10
356 10
AHF + IS sham injection
rat no. 42 43 44 45 46
hours 0 10 10 10 10 10
6 10 10 10 10 10
24 10 10
48 27 47 44 70
AHF + IP hepatocytes
rat no. 47 48 49 50 51
hours 0 10 10 10 10 10
6 5 5 5 5 5
30 30 24
48 56
60 45
70 65
150 5 18
216 5
rat no. 53 54 55 56 57
hours 0 5 5 5 5 5
6 5 5 5 5 5
48 28 44
69 85
rat no. 59 60 61 62 63
hours 0 5 5 5 5 5
6 5 5 5 5 5
24 5 5 21
48 32 40 57
87 44 78
rat no. 65 66 67 68 69
hours 0 5 5 5 5 5
6 5 5 5 5 5
24 5 26
39 43
45 70 60
54 73
70 52
AHF + IP cytosol (71) daily
rat no. 73
hours 0 0
24 28
72 19
100
74
0
0
13
193
AHF + IP cytosol (72) daily
rat no. 75 76
hours 0 0 48
6 15
24 10 0
48 69
100 10
AHF + IP cytosol (72) every 2nd day
rat no. 77 78 81 82
hours 0 0 15 10
6 0 0 15
25 16 10
48 75 40
72 76
148 12
AHF + IP cytosol (72) every 3rd day
rat no. 83 84
hours 0 10 0
6 10
54 75
72 80
AHF control
rat no. 79 80 86 87
hours 0 16 10 0 10
6 10 0 0
24 0
48 80
72 80
90 45
AHF + IV cytosol (85) daily
rat no. 88 89 90 91
hours 0 10 0 0 0
6 10 0 10 0
24 10 10 0 0
48 25
72 16 21
100 27 12 12 20
144 16 10 10 10
196 0 12 10 10
630 0 10 10 10
AHF + IV cytosol (93) daily
rat no. 95 96
hours 0 0 10
6 0 0
24 10 0
96 45
120 20 33
168
533
97
15
10
21
12
10
20
0
194
AHF + IV cytosol (94) daily
rat no. 98 99 100
hours 0 10 10 28
6 14 0 0
24 12 0 0
48 66 32 20
72 24 . 12
96 10 15
120 20 10
168 10 10
533 10 10
AHF + IV cytosol (92) daily
rat no. 101 102 103
hours 0 10 20 10
6 0 15
24 0 15 10
48 56 36
72 25 61 35
96 12 10
120 10 10
168 10 21
533 10 10
AHF + *V cytosol (94) daily after 12 hrs
rat no. 104 105 106
hours 0 10 10 10
12 0
24 30
48 30 45 20
72 14
96 25 15
144 15 10 0
216 10 0 10
365 10 0 10
AHF + IV cytosol (94) daily after 6 hrs
rat no. 107 108 109
hours 0 30 36 10
6 10 10
24 28
72 56
96 10 10
144 10 10
216 10 10
365 10
AHF + IV cytosol (94) daily after 24 hrs
rat no. 110 111 112
hours 0 0 0 10
24 28 36
48 21 63 -
72 14 26
96 10 12
144 10 10
216 10 10
365 10 10
195
AHF control 
rat no. 
hours 0
6
24
48
70
116
20
32
117
10
15
10
46
AHF + IV heat treated cytosol daily
rat no. 118 119 120
hours 0 10 10 25
6 20 20 20
24 14 10 40
72 10
90 20
102 10 27
AHF + IV cytosol (113) daily
rat no. 121 122 123 124 125
hours 0 20 21 20 10 10
6 21 15 10 45 14
24 35 10 20 10
48 83
102 10 20
144 10 10 25
192 35 10 10
365 10 16 10
AHF + IV dialysed cytosol (126) daily
rat no. 128 129 130 131 132 133
hours 0 10 33 28 10 28
6 10 10 42 10
24 10 20
60 43 28
65 35
70 71
90 43 36
AHF + IV heated cytosol (127,127a) daily 
rat no. 
hours 0
6 
24 
56 
60 
65 
75 
96 
120
134 135 136 137 138 139
20 10 10 10 10 10
25 20 35 10 20 28
33 77 35
46
40
49
14
43
33
196
AHF + IV cytosol (various) after 24 hrs and daily
rat no 
hours 0
24
48
55
60
168
216
312
360
141
15
10
49
142
10
143
15
144
10
68
10
15
5
10
AHF + IV cytosol (various) after 30 hrs and daily
rat no 
hours 0
30
40
48
81
147
10
25
148
10
30
149
10
52
150
10
58
145
20
50
151
10
33
AHF + IV saline
rat no. 140
hours 0 10
6
24 21
30
40 27
48
72
AHF + IV human cytosol
rat no 
hours 0
6
24
48
72
96
116
144
192
312
388
157
10
10
10
15
10
10
10
10
AHF + IV plasma daily
rat no 
hours 0
6
24
44
96
144
192
312
388
161
15
10
33
15
10
10
10
10
146
15
53
158
10
7
7
35
10
10
10
10
10
162
22
7
28
10
155
28
10
10
24
159
10
10
14
24
163
10
5
20
10
15
5
10
10
156
20
10.
10
15
22
160
20
10
10
55
22
164
10'
20
12
197
AHF + IP saline daily
rat no. 165 166 167 168
hours 0 10 10 10 10
6 20 10
24 10 55 15
44 14 17
48 19 34
AHF + IV saline and sacrifice
rat no. 169 182
hours 0 10 10
6 20 42
24 35 66
30 52
AHF + IV saline
rat no. 170 172 174 176
hours 0 10 10 10 20
6 10 10 10 10
24 10 10 10 10
72 34 46 94 59
AHF + IV cytosol (various) and sacrifice
rat no. 171 173 175 177
hours 0 10 3 10 10
6 10 10 10 10
24 10 20 10
48 20
72 10 48 51 35
AHF + IP Hanks single
rat no. 178 179 180 181
hours 0 10 10 10 15
6 10 20 10 35
24 10
48 32
53 63
57 61
72 36
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RAT DNA SYNTHESIS RESULTS
Experiment 1
Plates ^H disintegrations / minute
in 40^1 (mean)
C i) 6562 5410 7539 6503
ii) +EGF 54794 53987 53269 54016
iii) +TGFjS 1446 858 1442 1248
T i) +20c 5296 6379 6045 5906
ii) +60c 4655 6582 5066 5434
iii) +5c 9898 8005 7783 8562
iv) +60c+TGFj3 1527 1490 915 1310
V) +60C+EGF 76074 79094 72305 75824
Plates DNA concentration
in 100/il (mean)
C i) 0.52 0.47 0.58 0.52
ii) +EGF 0.88 0.80 0.825 0.84
iii) +TGF/Î 0.305 0.275 0.275 .0.285
T i) +20c 0.66 0.965 0.77 0.76
ii) +60c 0.605 0.725 0.66 0.66
iii) +5c 0.715 0.715 0.745 0.725
iv) +60C+TGF/5 0.25 0.14 0.495 0.295
v) +60C+EGF 0.965 1.13 1.045 1.05
Plates ^H disintegrations / jug DNA (mean)
C i) 31548 28777 32496 30940
ii) +EGF 155668 168709 161421 161932
iii) +TGFj3 11861 7800 13109 10923
T i) +20c 20057 16526 19627 18736
ii) +60c 19236 22087 19189 20170
iii) +5c 34608 27989 26117 29571
iv) +60C+TGF/3 15270 26607 4621 15499
v) +60C+EGF 197082 174985 172978 181681
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Experiment 2
Plates
T i 
ii 
iii 
iv
V
vi
vii
viii
ix
X
+5C+EGF 
+10C+EGF 
+30C+EGF 
+60C+EGF 
+ 5C+TGF/3 
+ 60c+TGFjS 
+5c 
+ 10c 
+3 Oc 
+60c
*H disintegrations / minute 
in 40/il
60381
25880
34639
2406
3429
2680
24420
25136
54368
56494
44934
28598
30764
2350
3889
2837
24263
36332
52641
56950
60714
27962
35797
2235
3057
3918
22593
38023
54261
(mean)
C i) 3242 4798 6172 4737
ii) +EGF 68111 73038 12210 51119
iii) +TGF/5 2607 2457 3813 2959
T i) +5C+EGF 68810 72516 69684 '70336
ii) +10C+EGF 44928 54981 62633 54179
iii) +30C+EGF 45952 56270 72130 58116
iv) +60+EGF 70650 58317 77737 68901
V) +5C+TGF/3 4099 4144 3665 3969
vi) +60c+TGFiS 5924 6859 5500 6094
vii) +5c 4790 5310 6738 5612
viii) + 10c 4679 5231 2431 4113
ix) +30c 4816 8705 6373 6631
x) +60c 13679 11981 13652 13104
Plates DNA concentrations 
in lOOjul (mean)
C i) 1.08 1.38 1.26 1.24
ii) +EGF 1.70 1.83 1.08 1.54
iii) +TGFjS 1.02 0.93 1.05 1.0
T i) +5C+EGF 2.85 3.21 3.06 3.04
ii ) +10C+EGF 3.06 3.06 2.58 2.9
iii) +30C+EGF 4.44 4.92 6.45 5.27
iv) +60C+EGF 5.10 4.74 5.43 . 5.09
V) +5c+TGFjS 4.26 4.41 4.10 4.26
vi ) +60C+TGF/3 4.32 4.41 4.50 4.41
vii) +5c 4.47 4.68 4.30 4.48
viii) + 10c 0.48 0.54 0.27 0.43
ix) +30c 0.48 0.60 0.42 0.50
X) +60c 0.63 0.57 0.63 0.61
Plates disintegrations / jug DNA (mean)
C i) 7512 8697 12256 9488
ii) +EGF 100104 99834 99968
iii ) +TGFj3 6397 6612 9086 7365
57941
52823
27479
33733
2330
3457
3144
23757
33163
53756
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Experiment 3
Plates disintegrations / minute
C i) (a) 6419
in 40/il 
5743 5023
(mean)
5728
ii ) (b) 3761 3902 4091 3918
iii) +EGF (b) 32050 41101 38127 37092
T i) +5c (a) 5943 5627 4963 5511
ii) +10c (a) 6655 5233 7131 6339
iii) +60c (a) 1878 5630 2990 3533
iv) +5c (b) 5900 6083 6449 6144
V) +10c (b) 6838 6630 6103 6523
vi) +60c (b) 6072 4870 3517 4819
vii) +5C+EGF (a) 58243 21853 58168 46088
viii) +10C+EGF (a) 60112 66563 58573 - 61749
ix) +60C+EGF (a) 48897 29625 35874 38132
x) +5C+EGF (b) 45462 53525 41556 46847
xi) +10C+EGF (b) 49090 48347 ' 46741 48059
xii) +60C+EGF (b) 50305 60786 36881 49324
Plates 
C i) (a)
DNA
0.56
concentration 
in lOOjul
0.62 0.46
(mean)
0.55
ii ) (b) 0.56 0.42 0.30 0.43
iii) +EGF (b) 0.45 0.54 0.49 0.49
T i) +5C (a) 0.49 0.45 0.49 0.48
ii ) + 10c (a) 0.68 0.59 0.66 0.64
iii) +60c (a) 0.63 0.51 0.59 0.57
iv) +5c (b) 0.63 0.63 0.66 0.64
v) +10c (b) 0.71 0.73 0.78 0.74
vi) +60c (b) 0.73 0.68 0.68 0.70
vii) +5C+EGF (a) 0.80 0.71 0.83 0.78
viii) +10C+EGF (a) 0.92 0.78 0.88 0.86
ix) +6 Oc+EGF (a) 1.09 0.95 0.85 0.96
X) +5C+EGF (b) 0.81 0.91 0.91 0.87
xi) +10C+EGF (b) 0.95 0.71 0.83 0.83
xii) +60C+EGF (b) 1.00 1.07 0.83 0.86
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Plates disintegrations / jug DNA (mean)
C i) (a) 28444 23437 268712 26251
ii ) (b) 16666 23287 34341 24765
iii ) +EGF (b) 180828 190299 193921 188350
T i) +5c (a) 30227 31747 25242 29072
ii) +10c (a) 24280 22234 26969 24495
iii) +60c (a) 7373 24948 12704 15008
iv) +5c (a) 23162 23880 24390 23811
v) +10c (a) 24096 22592 19508 22065
vi) +60c (a) 20690 17767 12831 17096
vii) +5C+EGF (a) 180588 77007 175097 144231
viii) +10C+EGF (a) 162051 212774 166602 180476
ix) +60C+EGF (a) 111448 77831 104928 98069
x) +5C+EGF (b) 140959 148162 115031 134717
xi) +10C+EGF (b) 128970 170369 140700 146680
xii) +6Oc+EGF (b) 125762 141673 111019 126151
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